10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2022

or

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                     to                    

Commission File Number: 001-34703

Alimera Sciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware	20-0028718
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
6310 Town Square, Suite 400 Alpharetta, GA	30005
(Address of principal executive offices)	(Zip Code)

(678) 990-5740

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 par value per share	ALIM	The Nasdaq Stock Market LLC (Nasdaq Global Market)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes  x    No  o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  x    No  o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	o	Accelerated filer	o
Non-accelerated filer	x	Smaller reporting company	x
		Emerging growth company	o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  o  No  x

As of May 10, 2022, there were 7,002,961 shares of the registrant’s Common Stock issued and outstanding.

1

ALIMERA SCIENCES, INC.

QUARTERLY REPORT ON FORM 10-Q

INDEX

PART I. FINANCIAL INFORMATION
Item 1. Financial Statements (unaudited)	6
Condensed Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021	6
Condensed Consolidated Statements of Operations for the three months ended March 31, 2022 and 2021	7
Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2022 and 2021	8
Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and 2021	9
Condensed Consolidated Statements of Changes in Stockholders’ Deficit	10
Notes to Condensed Consolidated Financial Statements	11
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	29
Item 3. Quantitative and Qualitative Disclosures about Market Risk	41
Item 4. Controls and Procedures	41
PART II. OTHER INFORMATION
Item 1. Legal Proceedings	42
Item 1A. Risk Factors	42
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	42
Item 3. Defaults Upon Senior Securities	42
Item 4. Mine Safety Disclosures	42
Item 5. Other Information	42
Item 6. Exhibits	43
Signatures	44

‎

2

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND PROJECTIONS

Various statements in this report of Alimera Sciences, Inc. (we, our, Alimera or the Company) are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this report regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. These statements are subject to risks and uncertainties and are based on information currently available to our management. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “contemplates,” “predict,” “project,” “target,” “likely,” “potential,” “continue,” “ongoing,” “will,” “would,” “should,” “could,” or the negative of these terms and similar expressions or words, identify forward-looking statements. The events and circumstances reflected in our forward-looking statements may not occur and actual results could differ materially from those projected in our forward-looking statements.

All written and oral forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. We caution investors not to rely too heavily on the forward-looking statements we make or that are made on our behalf. We undertake no obligation and specifically decline any obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Please see, however, any further disclosures we make on related subjects in any annual, quarterly or current reports that we may file with the Securities and Exchange Commission (SEC).

We encourage you to read the discussion and analysis of our financial condition and the accompanying unaudited interim condensed consolidated financial statements and notes thereto (Interim Financial Statements) contained in this Quarterly Report on Form 10-Q and our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021, which we filed with the SEC on March 23, 2022 (the 2021 Form 10-K). We also encourage you to read Item 1A of Part 1 entitled “Risk Factors” of the 2021 Form 10-K, which contains a more detailed discussion of some of the risks and uncertainties associated with our business. In addition to the risks summarized below and in “Risk Factors” in the 2021 Form 10-K, other unknown or unpredictable factors also could affect our results. There can be no assurance that we will in fact achieve the actual results or developments we anticipate or, even if we do substantially realize them, that they will have the expected consequences to, or effects on, us. Therefore, we can give no assurances that we will achieve the outcomes stated in those forward-looking statements and estimates. Meaningful factors that could cause actual results to differ include:

Operational Risks

•our dependence on the commercial success of our only product, ILUVIEN;

•the competition we face, given that the number of competitive products is growing and our competitors include larger, more established, fully integrated pharmaceutical companies and biotechnology companies that have substantially greater capital resources, existing competitive products, larger research and development staffs and facilities, greater marketing capabilities, and greater experience in drug development and in obtaining regulatory approvals than we do;

•uncertainty associated with our ability to retain our current employees and to recruit and retain the new employees we need in the future, in particular a productive sales force;

•the possibility that the NEW DAY Study may (a) fail to demonstrate the efficacy of ILUVIEN as baseline therapy in patients with early diabetic macular edema (DME) or to generate data demonstrating the benefits of ILUVIEN when compared to the current leading therapy for DME, and (b) take longer or be more costly to complete than we currently anticipate;

•our possible inability to expand our portfolio of ophthalmic products;

•the negative effects of inflation, which may increase the compensation we must pay to retain and attract a high-quality workforce and is likely to increase our operational costs;

Manufacturing Risks

•our dependence on third-party manufacturers to manufacture ILUVIEN or any future products or product candidates in sufficient quantities and quality, in a timely manner (particularly during the COVID-19 pandemic), and at an acceptable price;

•the possibility that we may fail to plan appropriately to meet the demand of our customers for ILUVIEN, which could lead either to (a) ILUVIEN being out of stock or (b) our investment of a greater amount of cash in inventory than we need;

•the possibility that the issues affecting global supply chains may negatively impact our ability to source materials and components to make ILUVIEN or to deliver ILUVIEN into our current markets;

•uncertainty associated with manufacturing components and materials being superseded or becoming obsolete;

3

Financial Risks

•the possibility that we may again fail to comply with the financial covenants in our $45.0 million Loan and Security Agreement with SLR Investment Corp. (SLR, f/k/a Solar Capital Ltd.) as Collateral Agent (Agent), and certain other lenders, including SLR in its capacity as a lender, dated December 31, 2019, as amended (the 2019 Loan Agreement), and in that event be unable to obtain a waiver from SLR for any resulting default;

•the possibility that we may not be able to refinance the 2019 Loan Agreement, which may lead to a greater amount of cash being required to support its amortization on a monthly basis beginning on January 1, 2023;

•our possible need to raise additional financing, the terms of which may restrict our operations and, if the capital we raise is equity or a debt security that is convertible into equity, could dilute our stockholders’ investment;

•uncertainty regarding our ability to achieve profitability and positive cash flow through the commercialization of ILUVIEN in the U.S., the European Economic Area (EEA) and other regions of the world where we sell ILUVIEN;

•a slowdown or reduction in our sales due to, among other things, a reduction in end user demand, unexpected competition, regulatory issues or other unexpected circumstances, including COVID-19;

•the risk that the planned discontinuation of LIBOR and the replacement of LIBOR with another reference rate may lead to increased interest costs;

•the effects of inflation on the floating interest rate we pay under the 2019 Loan Agreement, which could cause our financing costs to increase materially and thus adversely affect our financial results;

Risks Related to the COVID-19 Pandemic

•the adverse effects of the COVID-19 pandemic, and its unpredictable duration and severity, in the regions where we have customers, employees and distributors;

•the adverse effects of the COVID-19 pandemic on sales of ILUVIEN resulting from (a) limitations on in-person access to physicians for treatment imposed by governments or healthcare facilities and (b) the unwillingness of patients, many of whom suffer from diabetic macular edema or, in Europe and the U.K., non-infectious uveitis, to visit their physicians in person for fear of contracting the COVID-19 coronavirus;

•the financial uncertainty associated with the adverse effects of the COVID-19 pandemic and the duration and severity of those effects, which had an adverse effect on our revenue beginning late in the first quarter of 2020 and continuing to the date of this report to some degree, and if these adverse effects were to strengthen again in the future, they may (a) adversely affect our revenue, financial condition and cash flows, and (b) affect certain estimates we use to prepare our quarterly financial results, including impairment of intangible assets, the income tax provision and recoverability of certain receivables;

•the possibility that the manufacture or distribution of the ILUVIEN insert or applicator may be disrupted by government action related to COVID-19 or by the effect of the COVID-19 pandemic on our manufacturers’ or distributors’ workforces;

•the possibility that the restrictions placed on regulatory and pricing bodies will delay or defer market access for ILUVIEN as we seek to secure reimbursement;

•the possibility that the economic impact of the COVID-19 pandemic will lead to changes in reimbursement policies and reduce market access for ILUVIEN in countries where we sell ILUVIEN;

•the possibility that we may fail to maintain or modify as necessary our internal controls over financial reporting in the current environment in which we or our distributors are required to modify our standard business processes to take into account the current environment in light of the COVID-19 pandemic;

•the possibility that staffing shortages resulting from the COVID-19 pandemic will recur at the third-party manufacturers where the ILUVIEN implant is made and the ILUVIEN applicator is assembled and packaged that may lead to product shortages;

•the possibility of reduced efficiency and potential distractions of our employees resulting from the prolonged impact of the COVID-19 pandemic, and the resulting loss of productivity;

•the possibility that enrollment of patients in our NEW DAY Study may not occur as quickly as we anticipate;

•the possible delay in enrollment of patients in our pediatric study for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS);

4

Regulatory Risks

•uncertainty associated with our pursuit of reimbursement from local health authorities in certain countries for the recently obtained additional indication for ILUVIEN (for NIU-PS);

•delay in or failure to obtain regulatory approval and reimbursement of ILUVIEN or any future products or product candidates in additional markets where we do not currently sell ILUVIEN;

•uncertainty associated with our ability to meet any post market requirements for NIU-PS in the EEA;

•the possibility that we may fail to secure regulatory approval in the greater China market, which would have an adverse effect on our ability to receive our milestone payments under the Ocumension license agreement;

•uncertainty associated with our ability to successfully commercialize ILUVIEN following regulatory approval in additional markets; and

Intellectual Property Risks

•the possibility that we may be adversely affected by the expiration of patents that protect key aspects of ILUVIEN in the near-to medium-term.

 
‎

5

PART I. FINANCIAL INFORMATION

ITEM 1. Financial Statements (unaudited)

ALIMERA SCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

	March 31,		December 31,
	2022		2021
	(In thousands, except share and per share data)
CURRENT ASSETS:
Cash and cash equivalents	$	9,946	$	16,510
Restricted cash		33		34
Accounts receivable, net		18,776		19,128
Prepaid expenses and other current assets		3,546		3,809
Inventory		2,452		2,679
Total current assets		34,753		42,160
NON-CURRENT ASSETS:
Property and equipment, net		2,719		2,783
Right of use assets, net		1,624		1,710
Intangible asset, net		10,419		10,897
Deferred tax asset		134		137
Warrant asset		282		833
TOTAL ASSETS	$	49,931	$	58,520
CURRENT LIABILITIES:
Accounts payable	$	6,604	$	8,706
Accrued expenses		3,046		3,617
Notes payable		7,105		—
Finance lease obligations		251		269
Total current liabilities		17,006		12,592
NON-CURRENT LIABILITIES:
Notes payable, net of discount		36,245		43,080
Other non-current liabilities		5,283		5,453
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ DEFICIT:
Preferred stock, $.01 par value — 10,000,000 shares authorized at March 31, 2022 and December 31, 2021:
Series A Convertible Preferred Stock, 1,300,000 authorized and 600,000 issued and outstanding at March 31, 2022 and December 31, 2021; liquidation preference of $24,000 at March 31, 2022 and December 31, 2021		19,227		19,227
Common stock, $.01 par value — 150,000,000 shares authorized, 6,992,654 shares issued and outstanding at March 31, 2022 and 6,935,154 shares issued and outstanding at December 31, 2021		70		69
Additional paid-in capital		377,541		377,229
Accumulated deficit		(403,236)		(397,281)
Accumulated other comprehensive loss		(2,205)		(1,849)
TOTAL STOCKHOLDERS’ DEFICIT		(8,603)		(2,605)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	49,931	$	58,520

See Notes to Unaudited Interim Condensed Consolidated Financial Statements (Interim Financial Statements).

‎

6

ALIMERA SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	Three Months Ended
	March 31,
	2022		2021
	(In thousands, except share and per share data)
REVENUE:
PRODUCT REVENUE, NET	$	11,898	$	11,214
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION		(1,680)		(1,562)
GROSS PROFIT		10,218		9,652
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES		3,583		3,213
GENERAL AND ADMINISTRATIVE EXPENSES		3,240		3,413
SALES AND MARKETING EXPENSES		6,853		4,818
DEPRECIATION AND AMORTIZATION		689		638
OPERATING EXPENSES		14,365		12,082
LOSS FROM OPERATIONS		(4,147)		(2,430)
INTEREST EXPENSE AND OTHER		(1,364)		(1,343)
UNREALIZED FOREIGN CURRENCY GAIN, NET		108		125
CHANGE IN FAIR VALUE OF WARRANT ASSET		(552)		—
NET LOSS	$	(5,955)	$	(3,648)
NET LOSS PER SHARE — Basic and Diluted	$	(0.85)	$	(0.63)
WEIGHTED AVERAGE SHARES OUTSTANDING — Basic and Diluted		6,990,737		5,755,424

See Notes to Interim Financial Statements.

 
‎

7

ALIMERA SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

	Three Months Ended
	March 31,
	2022		2021
	(In thousands)
NET LOSS	$	(5,955)	$	(3,648)
OTHER COMPREHENSIVE LOSS
Foreign currency translation adjustments		(356)		(597)
TOTAL OTHER COMPREHENSIVE LOSS		(356)		(597)
COMPREHENSIVE LOSS	$	(6,311)	$	(4,245)

See Notes to Interim Financial Statements.

‎

8

ALIMERA SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	Three Months Ended
	March 31,
	2022		2021
	(In thousands)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(5,955)	$	(3,648)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		689		638
Unrealized foreign currency transaction gain, net		(108)		(125)
Amortization of debt discount and deferred financing costs		271		240
Stock-based compensation expense		312		262
Change in fair value of warrant asset		552		—
Changes in assets and liabilities:
Accounts receivable		184		1,335
Prepaid expenses and other current assets		265		(35)
Inventory		203		106
Accounts payable		(1,992)		(1,003)
Accrued expenses and other current liabilities		(541)		(259)
Other long-term liabilities		(93)		(12)
Net cash used in operating activities		(6,213)		(2,501)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment		(149)		(84)
Net cash used in investing activities		(149)		(84)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payment of finance lease obligations		(62)		(57)
Net cash used in financing activities		(62)		(57)
EFFECT OF EXCHANGE RATES ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH		(141)		(299)
NET CHANGE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH		(6,565)		(2,941)
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH — Beginning of period		16,544		11,242
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH — End of period	$	9,979	$	8,301
SUPPLEMENTAL DISCLOSURES:
Cash paid for interest	$	1,061	$	1,061
Cash paid for income taxes	$	18	$	4
Supplemental schedule of non-cash investing and financing activities:
Note payable end of term payment accrued but unpaid	$	2,250	$	2,250

See Notes to Interim Financial Statements.

9

ALIMERA SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

				Series A
				Convertible									Accumulated
	Common Stock			Preferred Stock			Additional		Common				Other
							Paid-In		Stock		Accumulated		Comprehensive
	Shares	Amount		Shares	Amount		Capital		Warrants		Deficit		Loss		Total
2021	(In thousands, except share data)
Balance, December 31, 2020	5,719,367	$	57	600,000	$	19,227	$	365,830	$	370	$	(392,909)	$	(553)	$	(7,978)
Issuance of common stock, net of issuance costs	45,000		1	—		—		—		—		—		—		1
Stock option exercises	58		—	—		—		—		—		—		—		—
Forfeitures of restricted stock	(10,933)		—	—		—		—		—		—		—		—
Stock-based compensation expense	—		—	—		—		262		—		—		—		262
Net loss	—		—	—		—		—		—		(3,648)		—		(3,648)
Foreign currency translation adjustments	—		—	—		—		—		—		—		(597)		(597)
Balance, March 31, 2021	5,753,492	$	58	600,000	$	19,227	$	366,092	$	370	$	(396,557)	$	(1,150)	$	(11,960)
2022
Balance, December 31, 2021	6,935,154	$	69	600,000	$	19,227	$	377,229	$	—	$	(397,281)	$	(1,849)	$	(2,605)
Issuance of common stock, net of issuance costs	57,500		1	—		—		—		—		—		—		1
Stock-based compensation expense	—		—	—		—		312		—		—		—		312
Net loss	—		—	—		—		—		—		(5,955)		—		(5,955)
Foreign currency translation adjustments	—		—	—		—		—		—		—		(356)		(356)
Balance, March 31, 2022	6,992,654	$	70	600,000	$	19,227	$	377,541	$	—	$	(403,236)	$	(2,205)	$	(8,603)

See Notes to Interim Financial Statements.

10

ALIMERA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. NATURE OF OPERATIONS

Alimera Sciences, Inc., together with its wholly owned subsidiaries (the Company), is a pharmaceutical company that specializes in the commercialization and development of ophthalmic pharmaceuticals. The Company was formed on June 4, 2003 under the laws of the State of Delaware.

The Company presently focuses on diseases affecting the retina, because the Company believes these diseases are not well treated with current therapies and affect millions of people globally. The Company’s only product is ILUVIEN^® (fluocinolone acetonide intravitreal implant) 0.19 mg, which has received marketing authorization and reimbursement in 24 countries for the treatment of diabetic macular edema (DME). In the U.S. and certain other countries outside Europe, ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. In 17 countries in Europe, ILUVIEN is indicated for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies. In addition, ILUVIEN has received marketing authorization in 17 European countries and reimbursement in five countries for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment (NIU-PS).

The Company markets ILUVIEN directly in the U.S., Germany, the U.K., Portugal and Ireland, and has made ILUVIEN available in the Nordic Region (Denmark, Finland, Norway and Sweden) with the support of an exclusive wholesaler. In addition, the Company has entered into various agreements under which distributors are providing or will provide regulatory, reimbursement and sales and marketing support for ILUVIEN in Austria, Belgium, the Czech Republic, France, Italy, Luxembourg, the Netherlands, Spain, Australia, New Zealand and several countries in the Middle East. In addition, the Company has granted an exclusive license to Ocumension Therapeutics for the development and commercialization of the Company’s 0.19mg fluocinolone acetonide intravitreal injection in China, East Asia and the Western Pacific.

Effects of the COVID-19 Pandemic

The public health crisis caused by the COVID-19 pandemic and the measures being taken by governments, businesses, and the public at large to limit the COVID-19 pandemic’s spread have had, and the Company expects will continue to have to some degree, certain negative effects on, and present certain risks to, the Company’s business. These limitations and other effects of the COVID-19 pandemic have had an adverse impact on the Company’s revenues beginning late in the first quarter of 2020 and continuing through the date of this report. These factors may continue to adversely impact the Company’s revenue, and the extent and duration of that impact is uncertain, particularly in light of the emergence of COVID-19 variants that may increase the transmissibility of the coronavirus or be more deadly, or both. Depending on the duration of these limitations and the severity and duration of other effects of the COVID-19 pandemic, the Company’s liquidity and financial condition may be adversely affected in the future as well. This uncertainty could have an impact in future periods on certain estimates used in the preparation of the Company’s quarterly financial results, including impairment of intangible assets, the income tax provision and realizability of certain receivables and the prospective compliance with the Company’s covenants in its loan agreement.

In response to the COVID-19 pandemic, the Company has implemented measures to mitigate the impact of the pandemic on its financial position and operations. These measures include the following:

•The Company is continuing to monitor the effects of the SARS-CoV-2 variants and to increase its engagement with its customers to mitigate any anticipated loss of revenue in those markets that may be affected.

•The Company is investing in e-marketing and in enhancing its capabilities to conduct meetings virtually as well as in person.

2. BASIS OF PRESENTATION

The Company has prepared the accompanying unaudited interim condensed consolidated financial statements and notes thereto (Interim Financial Statements) in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, these Interim Financial Statements do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of the Company’s management, the accompanying Interim Financial Statements reflect all adjustments, which include normal recurring adjustments, necessary to present fairly the Company’s interim financial information.

11

ALIMERA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The accompanying Interim Financial Statements and related notes should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2021 and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the SEC on March 23, 2022 (the 2021 Form 10-K). The financial results for any interim period are not necessarily indicative of the expected financial results for the full year.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company’s accounting policies followed for quarterly financial reporting are the same as those disclosed in the Notes to Financial Statements included in the 2021 Form 10-K.

Adoption of New Accounting Standard

In August 2020, the FASB issued Accounting Standards Update (ASU) 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This standard simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The standard requires entities to provide expanded disclosures about the terms and features of convertible instruments and amends certain guidance in ASC 260 on the computation of EPS for convertible instruments and contracts on an entity’s own equity. The standard became effective for the Company on January 1, 2022. The adoption of this guidance did not have a material impact on the Company’s financial statements.

Accounting Standards Issued but Not Yet Effective

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (ASC 326): Measurement of Credit Losses on Financial Instruments. This ASU replaces the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. The standard becomes effective for the Company on January 1, 2023. The Company does not anticipate the adoption of this ASU will have a material impact on its financial statements.

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (ASC 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This standard provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The standard is available until December 31, 2022. The Company does not anticipate the adoption of this ASU will have a material impact on the Company’s financial statements.

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The amendments in this ASU require that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers (ASC 606). The amendments in this ASU are effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company does not anticipate the adoption of this ASU will have a material impact on its financial statements.

4. REVENUE RECOGNITION

Overview

The Company recognizes revenue when a customer obtains control of the related good or service. The amount recognized reflects the consideration the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following steps as outlined in the guidance: (1) identify the contract with the customer, (2) identify the performance obligations within the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when the entity satisfies a performance obligation. At the inception of a contract, the contract is evaluated to determine if it falls within the scope of ASC 606, followed by the Company’s assessment of the goods or services promised within each contract, assessment of whether the promised good or service is distinct and determination of the performance obligations. The Company then recognizes revenue based on the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.

12

ALIMERA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions related to the performance obligations.

Net Product Sales

The Company sells its products to major pharmaceutical distributors, pharmacies, hospitals and wholesalers (collectively, its Customers). In addition to distribution agreements with Customers, the Company enters into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company’s products. The Company recognizes revenues from product sales at a point in time when the Customer obtains control, typically upon delivery. The Company accrues for fulfillment costs when the related revenue is recognized. Taxes collected from Customers relating to product sales and remitted to governmental authorities are excluded from revenues.

Estimates of Variable Consideration

Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for reserves related to statutory rebates to State Medicaid and other government agencies; commercial rebates and fees to Managed Care Organizations (MCOs), Group Purchasing Organizations (GPOs), distributors, and specialty pharmacies; product returns; sales discounts (including trade discounts); distributor costs; wholesaler chargebacks; and allowances for patient assistance programs relating to the Company’s sales of its products.

These reserves are based on estimates of the amounts earned or to be claimed on the related sales. Management’s estimates take into consideration historical experience, current contractual and statutory requirements, specific known market events and trends, industry data, and Customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the net sales price is limited to the amount that is probable not to result in a significant reversal in the amount of the cumulative revenue recognized in a future period. If actual results vary, the Company may adjust these estimates, which could have an effect on earnings in the period of adjustment.

With respect to the Company’s international contracts with third-party distributors, certain contracts have elements of variable consideration, and management reviews those contracts on a regular basis and makes estimates of revenue based on historical ordering patterns and known market trends and data. The amount of variable consideration included in net sales in each period could vary depending on the terms of these contracts and the probability of reversal in future periods.

Consideration Payable to Customers

Distribution service fees are payments issued to distributors for compliance with various contractually-defined inventory management practices or services provided to support patient access to a product. Distribution service fees reserves are based on the terms of each individual contract and are classified within accrued expenses and are recorded as a reduction of revenue.

Product Returns

The Company’s policies provide for product returns in the following circumstances: (a) expiration of shelf life on certain products; (b) product damaged while in the Customer’s possession; and (c) following product recalls. Generally, returns for expired product are accepted three months before and up to one year after the expiration date of the related product, and the related product is destroyed after it is returned. The Company may either refund the sales price paid by the Customer by issuing a credit or exchange the returned product for replacement inventory. The Company typically does not provide cash refunds. The Company estimates the proportion of recorded revenue that will result in a return by considering relevant factors, including historical returns experience, the estimated level of inventory in the distribution channel, the shelf life of products and product recalls, if any.

13

ALIMERA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The estimation process for product returns involves, in each case, several interrelating assumptions, which vary for each Customer. The Company estimates the amount of its product sales that may be returned by its Customers and records this estimate as a reduction of revenue from product sales in the period the related revenue is recognized, and because this returned product cannot be resold, there is no corresponding asset for product returns. To date, product returns have been minimal.

License Revenue

The Company enters into agreements in which it licenses certain rights to its products to partner companies that act as distributors. The terms of the license agreement may include payment to the Company of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. The Company recognizes revenue from upfront payments at a point in time, typically upon fulfilling the delivery of the associated intellectual property to the customer.

The Company will recognize sales-based milestone payments as revenue upon the achievement of the cumulative sales amount specified in the contract in accordance with ASC 606. For those milestone payments which are contingent on the occurrence of particular future events, the Company determines that these need to be considered for inclusion in the calculation of total consideration from the contract as a component of variable consideration using the expected value method. As such, the Company assesses each milestone to determine the probability of and substance behind achieving each milestone. Given the inherent uncertainty associated with these future events, the Company will not recognize revenue from such milestones until there is a high probability of occurrence, which typically occurs near or upon achievement of the event.

Customer Payment Obligations

The Company receives payments from its Customers based on billing schedules established in each contract, which vary across the Company’s markets, but generally range between 30 to 120 days. Occasionally, the Company extends the timing of its receipt of payment from the Company’s international Customers. Amounts are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation is that the Customer will pay for the product or services in one year or less of receiving those products or services.

5. LEASES

The Company evaluates all of its contracts to determine whether it is or contains a lease at inception. The Company reviews its contracts for options to extend, terminate or purchase any right of use assets and accounts for these, as applicable, at inception of the contract. Upon adoption of ASC 842, the Company elected the transition package of three practical expedients permitted within the standard. In accordance with the package of practical expedients, the Company did not reassess initial direct costs, lease classification or whether its contracts contain or are leases. The Company made an accounting policy election not to recognize right of use assets and liabilities for leases with a term of 12 months or less, or those that do not meet the Company’s capitalization threshold, unless the leases include options to renew or purchase the underlying asset that are reasonably certain to be exercised. Lease costs associated with those leases are recognized as incurred. The Company has also chosen the practical expedient that allows it to combine lease and non-lease components as a single lease component.

Lease renewal options are not recognized as part of the lease liability until the Company determines it is reasonably certain it will exercise any applicable renewal options. The Company has determined it is not reasonably certain it will exercise any applicable renewal options. The Company has not recorded any liability for renewal options in these consolidated financial statements. The useful lives of leased assets as well as leasehold improvements, if any, are limited by the expected lease term.

Operating Leases

The Company’s operating lease activities primarily consist of leases for office space in the U.S., the U.K., Ireland and Germany. Most of these leases include options to renew, with renewal terms generally ranging from one to eight years. The exercise of lease renewal options is at the Company’s sole discretion. Certain of the Company’s operating lease agreements include variable lease costs that are based on common area maintenance and property taxes. The Company expenses these payments as incurred. The Company’s operating lease agreements do not contain any material residual value guarantees or material restrictive covenants.

14

ALIMERA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Supplemental balance sheet information as of March 31, 2022 and December 31, 2021 for the Company’s operating leases is as follows:

	March 31,		December 31,
	2022		2021
	(In thousands)
NON-CURRENT ASSETS:
Right of use assets, net	$	1,624	$	1,710
Total lease assets	$	1,624	$	1,710
CURRENT LIABILITIES:
Accrued expenses	$	323	$	220
NON-CURRENT LIABILITIES:
Other non-current liabilities		2,618		2,735
Total lease liabilities	$	2,941	$	2,955

The Company’s operating lease cost for the three months ended March 31, 2022 was $138,000 and is included in general and administrative expenses in its condensed consolidated statement of operations. The Company’s operating lease cost for the three months ended March 31, 2021 was $118,000 and is included in general and administrative expenses in its condensed consolidated statement of operations.

As of March 31, 2022, a schedule of maturity of lease liabilities under all of the Company’s operating leases is as follows:

Years Ending December 31	(In thousands)
2022 (remaining)	$	201
2023		716
2024		687
2025		474
2026		488
Thereafter		1,555
Total		4,121
Less amount representing interest		(1,180)
Present value of minimum lease payments		2,941
Less current portion (as a portion of accrued expenses)		(323)
Non-current portion (as a portion of other non-current liabilities)	$	2,618

Cash paid for operating leases was $68,000 during the three months ended March 31, 2022. No right-of-use assets were obtained in connection with operating leases for the three months ended March 31, 2022. Cash paid for operating leases was $149,000 during the three months ended March 31, 2021. No right-of-use assets were obtained in connection with operating leases for the three months ended March 31, 2021.

As of March 31, 2022, the weighted average remaining lease terms of the Company’s operating leases was 6.9 years. The weighted average discount rate used to determine the lease liabilities was 9.5%.

Finance Leases

The Company’s finance lease activities primarily consist of leases for office equipment and automobiles. Property and equipment leases are capitalized at the lesser of fair market value or the present value of the minimum lease payments at the inception of the leases using the Company’s incremental borrowing rate. The Company’s finance lease agreements do not contain any material residual value guarantees or material restrictive covenants.

15

ALIMERA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Supplemental balance sheet information as of March 31, 2022 and December 31, 2021 for the Company’s finance leases is as follows:

	March 31,		December 31,
	2022		2021
	(In thousands)
NON-CURRENT ASSETS:
Property and equipment, net	$	302	$	392
Total lease assets	$	302	$	392
CURRENT LIABILITIES:
Finance lease obligations	$	251	$	269
NON-CURRENT LIABILITIES:
Finance lease obligations — less current portion		181		225
Total lease liabilities	$	432	$	494

Depreciation expense associated with property and equipment under finance leases was approximately $94,000 and $101,000 for the three months ended March 31, 2022 and 2021, respectively. Interest expense associated with finance leases was $14,000 for the three months ended March 31, 2022 and 2021.

As of March 31, 2022, a schedule of maturity of lease liabilities under finance leases, together with the present value of minimum lease payments, is as follows:

Years Ending December 31	(In thousands)
2022 (remaining)	$	279
2023		236
Total		515
Less amount representing interest		(83)
Present value of minimum lease payments		432
Less current portion		(251)
Non-current portion	$	181

Cash paid for finance leases was $98,000 during the three months ended March 31, 2022. No property or equipment was obtained in exchange for finance leases during the three months ended March 31, 2022.

As of March 31, 2022, the weighted average remaining lease terms of the Company’s finance leases was 0.9 years. The weighted average discount rate used to determine the finance lease liabilities was 9.4%.

6. GOING CONCERN

The accompanying Interim Financial Statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Interim Financial Statements do not include any adjustments that might result from the outcome of this uncertainty.

To date, the Company has incurred recurring losses and has accumulated a deficit of $403,236,000 from inception through March 31, 2022. As of March 31, 2022, the Company had approximately $9,946,000 in cash and cash equivalents.

Further, the Company must maintain compliance with the debt covenants of its $45,000,000 Loan and Security Agreement dated December 31, 2019 with SLR Investment Corp., as amended (the 2019 Loan Agreement; see Note 10). In management’s opinion, the uncertainty regarding future revenues raises substantial doubt about the Company’s ability to continue as a going concern without access to additional debt and/or equity financing over the course of the next twelve months.

The Company’s operations and thus its net product revenues have continued to be adversely affected by the COVID-19 pandemic. During the six months ended December 31, 2021 and September 30, 2021, the Company did not generate sufficient revenue to meet the trailing six-month revenue covenant included in the 2019 Loan Agreement. The lenders provided a consent that permitted the Company not

16

ALIMERA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

to maintain the revenue covenant as of December 31, 2021 and September 30, 2021 and waived any event of default that has occurred or may be deemed to have occurred.

The Company met the trailing six-month revenue covenant included in the 2019 Loan Agreement for the six-month period ended March 31, 2022 and expects to comply with the revenue covenant at the next reportable date, which is June 30, 2022, and through one year after the filing date of this Quarterly Report on Form 10-Q, although the Company can give no assurances in that regard. Due to the remaining uncertainty surrounding the COVID-19 pandemic, it is possible that the Company will fail to comply with the revenue covenant. If the Company fails to comply with the revenue covenant and the lenders do not provide a consent and waiver, acceleration of the maturity of the loan is one of the remedies available to the lenders. If the lenders accelerate the maturity of the loan, the Company would be forced to find alternative financing or enter into an alternative agreement with the lenders. The Company cannot be sure that alternative financing will be available when needed or that, if available, the alternative financing could be obtained on terms that are not significantly detrimental to the Company or its stockholders.

To meet the Company’s future working capital needs, the Company may need to raise additional debt or equity financing. While the Company from time to time has been able to raise additional capital through issuance of equity and/or debt financing, the Company cannot guarantee that it will be able to maintain debt compliance, raise additional equity, contain or reduce expenses, or increase revenue. Accordingly, there is substantial doubt about the Company’s ability to continue as a going concern within one year after these Interim Financial Statements are issued.

7. INVENTORY

Inventory consisted of the following:

	March 31,		December 31,
	2022		2021
	(In thousands)
Component parts (1)	$	157	$	200
Work-in-process (2)		684		1,416
Finished goods		1,611		1,063
Total Inventory	$	2,452	$	2,679

(1)    Component parts inventory consists of manufactured components of the ILUVIEN applicator.

(2)    Work-in-process consists of completed units of ILUVIEN that are undergoing, but have not completed, quality assurance testing or stability testing as required by U.S. or EEA regulatory authorities.

8. INTANGIBLE ASSET

As a result of the approval of ILUVIEN by the U.S. Food and Drug Administration (FDA) in 2014, the Company was required to pay EyePoint Pharmaceuticals, Inc. (EyePoint) a milestone payment of $25,000,000 (see Note 9).

The gross carrying amount of the intangible asset is $25,000,000, which is being amortized over approximately 13 years from the payment date. The amortization expense related to the intangible asset was approximately $489,000 for both the three months ended March 31, 2022 and 2021, respectively. The net book value of the intangible asset was $10,419,000 and $10,897,000 as of March 31, 2022 and December 31, 2021, respectively.

17

ALIMERA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The estimated future amortization expense as of March 31, 2022 for the remaining periods in the next five years and thereafter is as follows:

Years Ending December 31	(In thousands)
2022 (remaining)	$	1,462
2023		1,940
2024		1,946
2025		1,940
2026		1,940
Thereafter		1,191
Total	$	10,419

9. LICENSE AGREEMENTS

EyePoint Agreement

In February 2005, the Company entered into an agreement with EyePoint (formerly known as pSivida US, Inc.) for the use of fluocinolone acetonide (FAc) in EyePoint’s proprietary insert technology. This agreement was subsequently amended a number of times (as amended, the EyePoint Agreement). The EyePoint Agreement provides the Company with a worldwide exclusive license to utilize certain underlying technology used in the development and commercialization of ILUVIEN.

In July 2017, the Company amended and restated its EyePoint license agreement, which was made effective July 1, 2017 (the New Collaboration Agreement). Under the New Collaboration Agreement, the Company has the right to the technology underlying ILUVIEN for the treatment of (a) human eye diseases, including uveitis, in Europe, the Middle East, and Africa, and (b) human eye diseases other than uveitis worldwide. The New Collaboration Agreement converted the Company’s previous profit share obligation to a royalty payable on global net revenues of ILUVIEN.

Following the signing of the New Collaboration Agreement, the Company retained a right to recover up to $15,000,000 of commercialization costs that were incurred prior to profitability of ILUVIEN and to offset a portion of future payments owed to EyePoint with these accumulated commercialization costs, referred to as the Future Offset. Due to the uncertainty of future net profits, the Company has fully reserved the Future Offset in the accompanying Interim Financial Statements. In March 2019, pursuant to the New Collaboration Agreement, the Company forgave $5,000,000 of the Future Offset in connection with the approval of ILUVIEN for NIU-PS in the U.K. As of March 31, 2022, the balance of the Future Offset was approximately $7,324,000.

During each of the three months ended March 31, 2022 and 2021, the Company’s net royalty expense payable to EyePoint was 5.2%, which was reduced from 6% due to the recoverable balance of the Future Offset. The Company is required to pay an additional 2% royalty on future global net revenues and other related consideration in excess of $75,000,000 in any year. During the three months ended March 31, 2022, the Company recognized approximately $617,000 of royalty expense, which is included in cost of goods sold, excluding depreciation and amortization. As of March 31, 2022, approximately $617,000 of this royalty expense was included in the Company’s accounts payable. During the three months ended March 31, 2021, the Company recognized approximately $584,000 of royalty expense, which is included in cost of goods sold, excluding depreciation and amortization.

Ocumension License Agreement

On April 14, 2021, the Company entered into an exclusive license agreement (the License Agreement) with Ocumension (Hong Kong) Limited (“Ocumension HK”), a wholly owned subsidiary of Ocumension Therapeutics, for the development and commercialization under Ocumension HK’s own brand name(s), either directly or through its affiliates or approved third-party sublicensees, of the Company’s 190 microgram fluocinolone acetonide intravitreal implant in applicator (the “Product”; currently marketed in the United States, Europe, and the Middle East as “ILUVIEN®”) for the treatment and prevention of eye diseases in humans, other than uveitis, in a specified territory. The “Territory” is defined as the People’s Republic of China, including Hong Kong SAR and Macau SAR, region of Taiwan, South Korea, Brunei, Cambodia, East Timor, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, and Vietnam.

18

ALIMERA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The Company received a nonrefundable upfront payment of $10,000,000 from Ocumension HK and may in the future receive additional sales-based milestone payments totaling up to $89,000,000 upon the achievement by Ocumension HK of certain specified sales milestones during the term of the License Agreement. The Company’s receipt of future milestone payments depends upon whether Ocumension HK is able to successfully complete product development and commercialization in the Territory, which requires, among other things, obtaining necessary regulatory approvals and appropriate reimbursement pricing in the various countries and jurisdictions in the Territory, a process that may take several years. During the year ended December 31, 2021, the Company recognized $11,048,000 in license revenue from the Ocumension transaction (including the value of a warrant subscription agreement, which Alimera received as consideration, for Alimera to purchase 1,000,000 shares of Ocumension Therapeutics during a period of four years), in accordance with ASC 606, Revenue from Contracts with Customers, with the remaining approximate $300,000 in consideration classified as deferred revenue that will be recognized over the remaining term of the license agreement once Ocumension begins to sell products.

The term of the License will continue (a) until the 10th anniversary of the latest first commercial sale of the Product in any country or jurisdiction in the Territory or (b) for as long as Ocumension HK is commercializing the Product in any part of the Territory, whichever is later. The term is subject to the Company’s right to partially terminate the Agreement beginning on the 10th anniversary of the effective date with respect to any country or jurisdiction in the Territory in which Ocumension has not achieved at the time of termination first commercial sale and is not continuing to commercialize the Product. Ocumension will purchase Product from the Company at a fixed transfer price without royalty obligation on future sale (other than milestone payments as described above). Ocumension HK is responsible for all costs of development and commercialization in the Territory.

When the Company entered into the license agreement, it also entered into a share purchase agreement and a warrant subscription agreement (warrant agreement), which are discussed in Note 16.

10. LOAN AGREEMENTS

Loan Agreements with SLR Investment Corp. (formerly named Solar Capital Ltd.)

As of January 5, 2018, the Company entered into a $40,000,000 loan and security agreement with Solar Capital Ltd., as Collateral Agent, and the parties signatory thereto from time to time as Lenders, including Solar Capital Ltd. in its capacity as a Lender (the 2018 Loan Agreement). On December 31, 2019, the Company refinanced the 2018 Loan Agreement by entering into a $45,000,000 loan and security agreement (as amended, the 2019 Loan Agreement) with Solar Capital Ltd., as Collateral Agent, and the parties signing the Loan Agreement from time to time as Lenders, including Solar Capital Ltd. in its capacity as a Lender (collectively, the Lenders). Under the 2019 Loan Agreement, the Company borrowed $42,500,000 on December 31, 2019 and borrowed the remaining $2,500,000 on February 21, 2020. The two borrowings under the 2019 Loan Agreement totaled $45,000,000 and are referred to as the SLR Loan, given that Solar Capital Ltd. changed its name to SLR Investment Corp. (SLR) in February 2021. The SLR Loan matures on July 1, 2024. The Company used the initial proceeds of the SLR Loan to pay off the outstanding loan under the 2018 Loan Agreement, along with related prepayment, legal and other fees and expenses of approximately $2,300,000, which included $2,200,000 in fees to SLR.

2018 Exit Fee Agreement

Notwithstanding the repayment of the outstanding loan under the 2018 Loan Agreement with part of the SLR Loan, the Company remains obligated to pay additional fees under the Exit Fee Agreement (2018 Exit Fee Agreement) dated as of January 5, 2018 by and among the Company, SLR, as Agent, and the Lenders. The 2018 Exit Fee Agreement survived the termination of the 2018 Loan Agreement upon the repayment of the outstanding loan under the 2018 Loan Agreement and has a term of 10 years. The Company is obligated to pay up to, but no more than, $2,000,000 in fees under the 2018 Exit Fee Agreement.

Specifically, the Company is obligated to pay an exit fee of $2,000,000 on a “change in control” (as defined in the 2018 Exit Fee Agreement). To the extent that the Company has not already paid the $2,000,000 fee, the Company is also obligated to pay a fee of $1,000,000 on achieving each of the following milestones:

• first, if the Company achieves revenues of $80,000,000 or more from the sale of its ILUVIEN product in the ordinary course of business to third party customers, measured on a trailing 12-month basis during the term of the agreement, tested at the end of each month; and

19

ALIMERA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

• second, if the Company achieves revenues of $100,000,000 or more from the sale of its ILUVIEN product in the ordinary course of business to third party customers, measured in the same manner.

2019 Exit Fee Agreement

The Company is also obligated to pay additional fees under the Exit Fee Agreement dated as of December 31, 2019 by and among the Company, SLR as Agent, and the Lenders (2019 Exit Fee Agreement). The 2019 Exit Fee Agreement will survive the termination of the 2019 Loan Agreement and has a term of 10 years. The Company will be obligated to pay a $675,000 exit fee upon the occurrence of an exit event, which generally means a change in control, as defined in the 2019 Exit Fee Agreement.

First Amendment to 2019 Loan Agreement

On May 1, 2020, the Company entered into a First Amendment (the First Amendment) to the 2019 Loan Agreement. The First Amendment also included revised covenants that applied to the Company’s financial performance during 2020, all of which were met. The First Amendment, among other things, required that a revenue covenant be measured at March 31, 2021 and at the last day of each quarter thereafter, with the minimum revenue amount equal to a percentage of the Company’s projected revenues in accordance with a plan the Company submitted to the Collateral Agent in February 2021, and with such plan to be approved by the Company’s board of directors (the Board) and SLR in its sole discretion.

Second Amendment to 2019 Loan Agreement

On March 30, 2021, the Company entered into a Second Amendment (the Second Amendment) to the 2019 Loan Agreement. The Second Amendment, among other things:

(a)reflected the Collateral Agent’s consent to the Company’s delivery of Board-approved annual financial projections for 2021 by April 1, 2021 (which the Company delivered in a timely manner);

(b)specified the minimum revenue amount, calculated on a trailing six-month basis and tested at the end of each calendar quarter in 2021, that the Company must achieve for each such period (the Revenue Covenant);

(c)required that the Revenue Covenant be tested at March 31, 2022 and at the last day of each quarter thereafter, with the minimum revenue amount equal to a percentage of the Company’s projected revenues in accordance with an annual plan that the Company must submit to the Collateral Agent by January 15th of such year, such plan to be approved by the Board and the Collateral Agent in its sole discretion; and

(d)provided that in future years the Company must deliver to the Collateral Agent and the Lenders as soon as available after approval thereof by the Board, but no later than the earlier of (x) 15 days after such approval and (y) February 28 of such year, the Company’s annual financial projections for the entire current fiscal year as approved by the Board; provided that any revisions to such projections approved by the Board shall be delivered to the Collateral Agent and the Lenders no later than seven days after such approval.

Third Amendment to 2019 Loan Agreement

On February 22, 2022, the Company entered into a Third Amendment to the 2019 Loan Agreement (the Third Amendment), which, among other things:

(a)specified the minimum revenue amount, calculated on a trailing six-month basis and tested at the end of each calendar quarter in 2022, that the Company must achieve for each such period (the Revenue Covenant);

(b)consented to maintaining a lower minimum revenue amount under the Revenue Covenant for the trailing six-month period ended December 31, 2021 than previously required under the 2019 Loan Agreement (and waived any event of default that may have occurred or may be deemed to have occurred as a result of the Company’s lower revenue amount for that period); and

20

ALIMERA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

(c)required that the Revenue Covenant be tested at March 31, 2023 and at the last day of each quarter thereafter, with the minimum revenue amount equal to a percentage of the Company’s projected revenues in accordance with an annual plan that the Company must submit to the Collateral Agent by January 15 of such year, such plan to be thereafter approved by the Board and the Collateral Agent in its sole discretion no later than February 28 of such year.

Interest on the 2019 Loan Agreement is payable at the greater of (i) one-month LIBOR or (ii) 1.78%, in either case plus 7.65% per annum. As of March 31, 2022, the interest rate under the 2019 Loan Agreement was 9.43%. The 2019 Loan Agreement provides for interest only payments until January 1, 2023. If the Company meets certain revenue thresholds and no event of default shall have occurred and is continuing, the Company can extend the interest only period an additional six months, ending on June 30, 2023, followed by one year of monthly payments of principal and interest

The Company’s operations and thus its net product revenues have continued to be adversely affected by the COVID-19 pandemic. During each of the six months ended September 30, 2021 and December 31, 2021, the Company did not generate sufficient revenue to meet the trailing six-month Revenue Covenant included in the 2019 Loan Agreement. For each such six-month period, the Lenders provided a consent that permitted the Company not to maintain the Revenue Covenant as of September 30, 2021 and December 31, 2021, respectively, and waived any event of default that may have occurred or may have been deemed to have occurred. The Company was in compliance with the Revenue Covenant as of March 31, 2022 and expects to comply with the Revenue Covenant at the next reportable date, which is June 30, 2022, and throughout 2022, although the Company can give no assurances in that regard. See Note 6.

Modification of Debt

In accordance with the guidance in ASC 470-50, Debt, the Company entered into and accounted for the First Amendment, the Second Amendment and the Third Amendment as modifications and expensed, as they were incurred, legal costs associated with third parties as costs of the modifications. The Company did not capitalize any additional costs associated with the Amendments.

Paycheck Protection Program Loan

On April 22, 2020, the Company received a $1,778,000 loan (the PPP Loan) under the Paycheck Protection Program established by the U.S. Small Business Administration as part of the Coronavirus Aid, Relief and Economic Security Act, or the CARES Act. The PPP Loan was unsecured and was evidenced by a note in favor of HSBC Bank USA, National Association (HSBC) as the lender. On July 21, 2020, the Company submitted an application to HSBC for forgiveness of the PPP Loan. The PPP Loan was forgiven in its entirety, including interest, on April 16, 2021. As a result of forgiveness, the Company recognized a gain on extinguishment of debt of $1,792,000 during the year ended December 31, 2021.

Fair Value of Debt

The weighted average interest rates of the Company’s notes payable approximate the rate at which the Company could obtain alternative financing. Therefore, the carrying amount of the notes approximated their fair value at March 31, 2022 and December 31, 2021.

Hercules Loan Agreement and Related Warrant

In connection with the previous loan with Hercules Capital, Inc. (Hercules), on October 20, 2016, the Company issued a warrant to Hercules Capital, Inc. that granted Hercules the right to purchase up to 30,582 shares of the Company’s common stock at an exercise price of $16.35 per share. The right to exercise this warrant expired on October 20, 2021.

11. EARNINGS (LOSS) PER SHARE (EPS)

The Company follows ASC 260, Earnings Per Share (ASC 260), which requires the reporting of both basic and diluted earnings per share. Because the Company’s preferred stockholders participate in dividends equally with common stockholders (if the Company were to declare and pay dividends), the Company uses the two-class method to calculate EPS. However, the Company’s preferred stockholders are not contractually obligated to share in losses.

21

ALIMERA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Basic EPS is computed by dividing net income or loss available to stockholders by the weighted average number of shares outstanding for the period. Diluted EPS is calculated in accordance with ASC 260 by adjusting weighted average shares outstanding for the dilutive effect of common stock options, restricted stock units and warrants. In periods where a net loss is recorded, no effect is given to potentially dilutive securities, since the effect would be anti-dilutive.

Common stock equivalent securities that would potentially dilute basic EPS in the future, but were not included in the computation of diluted EPS because they were either not classified as participating or would have been anti-dilutive, were as follows:

	March 31,
	2022		2021
Series A convertible preferred stock		601,504		601,504
Common stock warrants		—		30,582
Stock options		1,315,161		1,083,124
Total		1,916,665		1,715,210

12. PREFERRED STOCK

Series A Convertible Preferred Stock

As of March 31, 2022, there were 600,000 shares of Series A Convertible Preferred Stock issued and outstanding.

13. EQUITY INCENTIVE PLANS

Under the Company’s 2019 Omnibus Incentive Plan (the 2019 Plan), the Compensation Committee of the Board is authorized to grant equity-based incentive awards that include stock options, restricted stock units (RSUs) and shares of restricted stock to officers, directors, employees and contractors. Equity-based awards are also outstanding under the Company’s 2010 Equity Incentive Plan, although no new awards can be granted under that plan. The Company also has an employee stock purchase plan.

Stock Options

During the three months ended March 31, 2022 and 2021, the Company recorded compensation expense related to stock options of approximately $258,000 and $235,000, respectively. As of March 31, 2022, the total unrecognized compensation cost related to non-vested stock options granted was $1,723,000 and is expected to be recognized over a weighted average period of 2.88 years. The following table presents a summary of stock option activity for the three months ended March 31, 2022 and 2021:

	Three Months Ended
	March 31,
	2022			2021
			Weighted			Weighted
			Average			Average
			Exercise			Exercise
	Options		Price ($)	Options		Price ($)
Options outstanding at beginning of period		1,075,795	23.35		939,379	26.72
Grants		283,550	4.84		187,150	5.02
Forfeitures and expirations		(44,184)	22.36		(43,347)	7.80
Exercises		—	—		(58)	6.75
Options outstanding at period end		1,315,161	19.39		1,083,124	23.73
Options exercisable at period end		810,201	27.92		739,466	31.30
Weighted average per share fair value of options granted during the period	$	3.32		$	3.22

22

ALIMERA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The following table provides additional information related to outstanding stock options as of March 31, 2022:

					Weighted
			Weighted		Average
			Average		Remaining		Aggregate
			Exercise		Contractual		Intrinsic
	Shares		Price ($)		Term		Value ($)
							(In thousands)
Outstanding		1,315,161		19.39		6.42 years		312
Exercisable		810,201		27.92		4.74 years		36
Outstanding, vested and expected to vest		1,247,294		20.15		6.26 years		277

The following table provides additional information related to outstanding stock options as of December 31, 2021:

					Weighted
			Weighted		Average
			Average		Remaining		Aggregate
			Exercise		Contractual		Intrinsic
	Shares		Price ($)		Term		Value ($)
							(In thousands)
Outstanding		1,075,795		23.35		5.56 years		21
Exercisable		809,837		28.76		4.57 years		5
Outstanding, vested and expected to vest		1,043,347		23.88		5.46 years		19

As of March 31, 2022, 686,603 shares remain available for grant under the 2019 Plan.

Restricted Stock and Restricted Stock Units

A summary of restricted stock and restricted stock units (RSU) transactions under the plans are as follows:

	Three Months Ended
	March 31,
	2022				2021
			Weighted				Weighted
			Average				Average
	Restricted		Grant Date		Restricted		Grant Date
	Stock & RSUs		Fair Value ($)		Stock & RSUs		Fair Value ($)
Restricted stock & RSUs outstanding at beginning of period		46,250		5.65		30,086		3.12
Grants		57,500		4.96		45,000		5.01
Vested units		(9,687)		5.01		(25,403)		3.12
Forfeitures		—		—		(10,933)		4.20
Restricted stock & RSUs outstanding at period end		94,063		5.29		38,750		5.01

23

ALIMERA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Employee stock-based compensation expense related to restricted stock and RSUs recognized in accordance with ASC 718, Compensation - Stock Compensation (ASC 718) was $46,000 and $19,000 for the three months ended March 31, 2022 and 2021, respectively.

As of March 31, 2022, the total unrecognized compensation cost related to restricted stock was $429,000 and is expected to be recognized over a weighted average period of 3.29 years.

Employee Stock Purchase Plan

During the three months ended March 31, 2022 and 2021, the Company recorded compensation expense related to its employee stock purchase plan of approximately $8,000 and $8,000, respectively.

14. INCOME TAXES

In accordance with ASC 740, Income Taxes, the Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities at the enacted tax rates in effect for the year in which the differences are expected to reverse. The Company records a valuation allowance against its net deferred tax asset to reduce the net carrying value to an amount that is more likely than not to be realized. At the end of each interim period, the Company makes its best estimate of the effective tax rate expected to be applicable for the full fiscal year. This estimate reflects, among other items, the Company’s best estimate of operating results and foreign currency exchange rates.

The Company also applies the provisions for income taxes related to, among other things, accounting for uncertain tax positions and disclosure requirements. There has been no change to the Company’s policy that recognizes potential interest and penalties related to uncertain tax positions. The Company conducts business globally and, as a result, files income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. In the normal course of business, the Company is subject to examination by taxing authorities throughout the world.

For the three months ended March 31, 2022, the Company has not recorded income tax expense or benefit. The Company has incurred losses in all material jurisdictions for the current quarter. No tax benefit is expected to be realized for the losses in the United States and the United Kingdom due to the ongoing losses and valuation allowances in these jurisdictions. Tax expense or benefit for income and losses in other jurisdictions (Ireland, Germany, and Portugal) are immaterial for the quarter.

At December 31, 2021, the Company had U.S. federal NOL carry-forwards of approximately $143,200,000 and state NOL carry-forwards of approximately $106,700,000 available to reduce future taxable income. The Company’s U.S. federal NOL carry-forwards remain fully reserved as of March 31, 2022. Except for the NOLs generated after 2017, the U.S. federal NOLs not fully utilized will expire at various dates between 2029 and 2038; most state NOL carry-forwards will expire at various dates between 2021 and 2041. Under the Tax Cuts and Jobs Act of 2017, U.S. federal NOLs and some state NOLs generated after 2017 will carryforward indefinitely.

As of December 31, 2021, the Company’s U.K. subsidiary is in a net deferred tax asset position primarily due to the step up in tax basis for intangible assets created by the transfer of intellectual property from the Netherlands to the U.K. Based upon the expected pattern of reversal of deferred taxes, it is not more likely than not that these deferred tax assets will be realized. As such, a full valuation allowance is placed against the net deferred tax assets of the U.K. subsidiary. The Company’s Irish subsidiary has a deferred tax asset for net operating loss carryforwards. The Company expects this net operating loss carryforward to be fully realizable in the future based upon the Company’s control of the transfer pricing arrangements. A valuation allowance is not recorded on the deferred tax assets of the Ireland subsidiary. Deferred tax considerations for all other foreign entities are immaterial to the financial statements.

The Company anticipates that its foreign subsidiaries will be profitable and have earnings in the future. Once the foreign subsidiaries have earnings, the Company intends to indefinitely reinvest in its foreign subsidiaries all undistributed earnings and original investments in such subsidiaries. As a result, the Company does not expect to record deferred tax liabilities in the future related to excesses of book over tax basis in the stock of its foreign subsidiaries in accordance with ASC 740-30-25.

Tax years from 2018 to 2020 remain subject to examination in California, Georgia, Kentucky, Tennessee, Texas and on the federal level, with the exception of the assessment of NOL carry-forwards available for utilization, which can be examined for all years since 2009.

24

ALIMERA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The statute of limitations on these years will close when the NOLs expire or when the statute closes on the years in which the NOLs are utilized.

15. SEGMENT INFORMATION

During the three months ended March 31, 2022 and 2021, two customers within the U.S. segment that are large pharmaceutical distributors accounted for 58% and 50%, respectively, of the Company’s consolidated product revenues. These same two customers within the U.S. segment accounted for approximately 58% and 68% of the Company’s consolidated accounts receivable at March 31, 2022 and at December 31, 2021, respectively.

During the first quarter of 2021, the Chief Executive Officer (CEO), who is the chief operating decision maker (CODM), changed the manner in which the CODM monitors performance, aligns strategies and allocates resources, which resulted in a change in the operating segments. The Company’s operations are now managed as three operating segments: U.S., International and Operating Cost. The Company determined that each of these operating segments represented a reportable segment. Previously, the Company was managed as two operating segments: U.S. and International. In monitoring performance, aligning strategies and allocating resources, the CODM manages and evaluates the Company’s U.S., International and Operating Cost segments based on segment income or loss from operations adjusted for certain non-cash items, such as stock-based compensation expense and depreciation and amortization. Therefore, the Company classifies within Other (a) the non-cash expenses included in research, development and medical affairs expenses; general and administrative expenses; and sales and marketing expenses; and (b) depreciation and amortization.

The Company’s U.S. and International segments represent the sales and marketing, general and administrative and research and development activities dedicated to the respective geographies. The Operating Cost segment primarily represents the general and administrative and research and development activities not specifically associated with the U.S. or International segments and includes expenses such as executive management; information technology administration and support; legal; compliance; clinical studies; and business development.

Each of the Company’s U.S., International and Operating Cost segments is separately managed and is evaluated primarily upon segment income or loss from operations. Other is presented to reconcile to the Company’s consolidated totals. The Company does not report balance sheet information by segment because the CODM does not review that information. The Company allocates certain operating expenses among its reporting segments based on activity-based costing methods. These activity-based costing methods require the Company to make estimates that affect the amount of each expense category that is attributed to each segment. Changes in these estimates will directly affect the amount of expense allocated to each segment and therefore the operating profit of each reporting segment.

The following tables present a summary of the Company’s reporting segments for the three months ended March 31, 2022 and 2021:

25

ALIMERA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

	Three Months Ended
	March 31, 2022
	U.S.		International		Operating Cost		Other		Consolidated
	(In thousands)
REVENUE:
PRODUCT REVENUE, NET	$	6,919	$	4,979	$	—	$	—	$	11,898
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION		(815)		(865)		—		—		(1,680)
GROSS PROFIT		6,104		4,114		—		—		10,218
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES		1,170		916		1,461		36		3,583
GENERAL AND ADMINISTRATIVE EXPENSES		317		422		2,283		218		3,240
SALES AND MARKETING EXPENSES		4,674		2,004		117		58		6,853
DEPRECIATION AND AMORTIZATION		—		—		—		689		689
OPERATING EXPENSES		6,161		3,342		3,861		1,001		14,365
SEGMENT INCOME (LOSS) FROM OPERATIONS		(57)		772		(3,861)		(1,001)		(4,147)
OTHER INCOME AND EXPENSES, NET		—		—		—		(1,808)		(1,808)
NET LOSS									$	(5,955)

	Three Months Ended
	March 31, 2021
	U.S.		International		Operating Cost		Other		Consolidated
	(In thousands)
REVENUE:
PRODUCT REVENUE, NET	$	5,647	$	5,567	$	—	$	—	$	11,214
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION		(751)		(811)		—		—		(1,562)
GROSS PROFIT		4,896		4,756		—		—		9,652
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES		725		941		1,538		9		3,213
GENERAL AND ADMINISTRATIVE EXPENSES		241		587		2,396		189		3,413
SALES AND MARKETING EXPENSES		3,278		1,334		143		63		4,818
DEPRECIATION AND AMORTIZATION		—		—		—		638		638
OPERATING EXPENSES		4,244		2,862		4,077		899		12,082
SEGMENT INCOME (LOSS) FROM OPERATIONS		652		1,894		(4,077)		(899)		(2,430)
OTHER INCOME AND EXPENSES, NET		—		—		—		(1,218)		(1,218)
NET LOSS									$	(3,648)

26

ALIMERA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

16. OTHER AGREEMENTS WITH OCUMENSION

Share Purchase Agreement

On April 14, 2021, the Company entered into a Share Purchase Agreement with Ocumension Therapeutics, pursuant to which the Company offered and sold to Ocumension 1,144,945 shares of common stock (the “Shares”), at a purchase price of $8.734044 per Share. The number of Shares sold was equal to 19.9% of the number of shares of common stock outstanding immediately before the closing.

The aggregate gross proceeds from the sale of the Shares were $10,000,000. The Company intends to use the net proceeds from the sale of the Shares to continue to commercialize ILUVIEN® and for general corporate purposes, which may include working capital, capital expenditures, other clinical trial expenditures, acquisitions of new technologies, products or businesses in ophthalmology, and investments.

Pursuant to the Share Purchase Agreement and subject to certain limited exceptions, Ocumension is prohibited from selling, transferring, or otherwise disposing of the Shares for a year following the closing date.

Ocumension is entitled to certain purchase rights if the Company elects to offer or sell new securities in either a private or public offering.

Warrant Subscription Agreement

On April 14, 2021, the Company entered into the warrant agreement with Ocumension Therapeutics pursuant to which Ocumension agreed to issue to the Company 1,000,000 non-transferable warrants granting the Company the right for a period of four years to subscribe to up to an aggregate of 1,000,000 shares of Ocumension stock at the subscription price of HK$23.88 per warrant share (or US$3.07 per warrant share as converted to U.S. Dollars at the exchange rate on April 9, 2021 of 0.12853 U.S. Dollars per HK$), subject to adjustment. (The converted rate is for illustrative purposes only; if the Company exercises the warrants, it will pay the subscription price of HK$23.88 per warrant share in HK$.) The warrants were issued on August 13, 2021, pursuant to the terms of the warrant agreement. The warrants are not and will not be listed on any stock exchange.

‎

27

ALIMERA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

17. FAIR VALUE

The Company applies ASC 820, Fair Value Measurements, in determining the fair value of certain assets and liabilities. Under this standard, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.

In determining fair value, the Company uses various valuation approaches. The hierarchy of those valuation approaches is broken down into three levels based on the reliability of inputs as follows:

Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. An active market for the asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. The valuation under this approach does not entail a significant degree of judgment.

Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include: quoted prices for similar assets or liabilities in active markets, inputs other than quoted prices that are observable for the asset or liability, (e.g., interest rates and yield curves observable at commonly quoted intervals or current market) and contractual prices for the underlying financial instrument, as well as other relevant economic measures.

Level 3 inputs are unobservable inputs for the asset or liability. Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.

The following fair value tables present information about the Company’s assets and liabilities measured at fair value on a recurring basis:

	March 31, 2022
	Level 1		Level 2		Level 3		Total
	(In thousands)
Assets:
Warrant asset (1)	$	—	$	282	$	—	$	282
Assets measured at fair value	$	—	$	282	$	—	$	282

	December 31, 2021
	Level 1		Level 2		Level 3		Total
	(In thousands)
Assets:
Warrant asset (1)	$	—	$	833	$	—	$	833
Assets measured at fair value	$	—	$	833	$	—	$	833

(1) The Company uses the Black-Scholes pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments. Changes in this value each reporting period are reported in the condensed consolidated statement of operations.

28

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with our unaudited interim condensed consolidated financial statements and the related notes (Interim Financial Statements) that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting our current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this report above.

Overview

Alimera Sciences, Inc., and its subsidiaries (we, our or us), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. We focus on diseases affecting the back of the eye, or retina, because we believe these diseases are not well treated with current therapies and affect millions of people globally. Our only product is ILUVIEN^®, which has received marketing authorization and reimbursement in numerous countries for the treatment of DME. In the U.S. and certain other countries outside Europe, ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. In 17 countries in Europe, ILUVIEN is indicated for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies. ILUVIEN is also now indicated in 17 countries in Europe for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).

We market ILUVIEN directly in the U.S., Germany, the U.K., Portugal and Ireland, and have made ILUVIEN available in the Nordic Region (Denmark, Finland, Norway and Sweden) with the support of an exclusive wholesaler. In addition, we have entered into various agreements under which distributors are providing or will provide regulatory, reimbursement and sales and marketing support for ILUVIEN in Austria, Belgium, the Czech Republic, France, Italy, Luxembourg, the Netherlands, Spain, Australia, New Zealand and several countries in the Middle East. In addition, we have granted an exclusive license to Ocumension Therapeutics for the development and commercialization of our 0.19mg fluocinolone acetonide intravitreal implant in China, East Asia and the Western Pacific.

Where We Market ILUVIEN to Treat Diabetic Macular Edema (DME)

ILUVIEN has received marketing authorization for the use of ILUVIEN to treat DME for the indications and in the countries shown in the following table:

Indication for the Treatment of DME	Countries Where ILUVIEN Has Received Marketing Authorization to Treat DME		Countries Where ILUVIEN Has Received Reimbursement Approval to Treat DME	Countries Where ILUVIEN is Currently Available to Treat DME
Treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure		U.S., Australia, Canada, Kuwait, Lebanon and the United Arab Emirates	U.S., Kuwait, Lebanon and the United Arab Emirates	U.S., Kuwait, Lebanon and the United Arab Emirates
Treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies		The United Kingdom (U.K.), Germany, France, Italy, Spain, Portugal, Ireland, Austria, Belgium, Denmark, Norway, Finland, Sweden, Poland, Czech Republic, the Netherlands and Luxembourg	The U.K., Germany, France, Italy, Spain, Portugal, Ireland, Luxembourg and the Netherlands	The U.K., Germany, France, Italy, Spain, Portugal, Ireland, Austria, Luxembourg, Denmark, Norway, Finland and the Netherlands

29

Where We Market ILUVIEN to Treat Recurrent Non-Infectious Uveitis Affecting the Posterior Segment of the Eye (NIU-PS)

ILUVIEN has received marketing authorization for the use of ILUVIEN to treat NIU-PS for the indications and in the countries shown in the following table:

Indication for the Treatment of NIU-PS	Countries Where ILUVIEN Has Received Marketing Authorization to Treat NIU-PS	Countries Where ILUVIEN Has Received Reimbursement Approval to Treat NIU-PS	Countries Where ILUVIEN is Currently Marketed to Treat NIU-PS
The prevention of relapse in recurrent NIU-PS	The U.K., Germany, France, Spain, Portugal, Ireland, Austria, Belgium, Denmark, Norway, Finland, Sweden, Poland, Czech Republic, the Netherlands and Luxembourg	The U.K., Germany, Ireland (private sector), Spain, Luxembourg and the Netherlands	The U.K. Germany, Ireland, Luxembourg, Denmark, Norway, Sweden, Finland and the Netherlands

We launched ILUVIEN for the NIU-PS indication in Germany and the U.K. during the third quarter of 2019, the Netherlands during the fourth quarter of 2020 and Luxembourg in the first quarter of 2021. In addition, we secured reimbursement of ILUVIEN for NIU-PS with the major private insurers in Ireland in the first quarter of 2021.

ILUVIEN became commercially available in Finland and Denmark during the first quarter of 2021 and in Norway during the second quarter of 2021. ILUVIEN is commercialized in the Nordic Region through a direct commercial team and our contracted wholesaler partner.

We signed an agreement on August 4, 2021 with Tanner Pharma to make ILUVIEN accessible to doctors wishing to use it on a named-patient basis in territories where ILUVIEN is not licensed or commercialized while ensuring compliance with regulations.

The COVID-19 Pandemic and Our Steps to Address its Effects on Our Business

The unprecedented events of the COVID-19 pandemic, and its unpredictable duration, in the regions where we have customers, employees and distributors have had an adverse effect on our sales of ILUVIEN and thus on our net revenues and may in the future have an adverse effect on our liquidity and financial condition. These adverse effects of the pandemic on us have resulted from the following, among other factors:

•Limitations imposed by governments and private parties on in-person access to physicians have adversely affected us in certain countries where ILUVIEN is currently marketed and may again do so if reimposed where they have been lifted.

•Patients’ concerns about their personal health during the COVID-19 pandemic have also negatively affected our business. Many DME patients have been hesitant or even unwilling to visit their physicians in person (even if otherwise permitted) for fear of contracting the COVID-19 coronavirus.

•Limitations on travel curtailed our in-person marketing activities, and may again do so if reimposed.

•As physicians gain increased access to patients as a result of the lifting of limitations in the U.K. and in Europe, they may give a higher priority to patients with acute illnesses before treating patients with chronic illnesses such as DME, thereby reducing or delaying the number of ILUVIEN treatments that might otherwise have been performed.

•SARS-CoV-2 variants such as Delta and Omicron have emerged and may again emerge, with unpredictable effects on our business.

These limitations and other effects of the COVID-19 pandemic have had an adverse impact on our revenues beginning late in the first quarter of 2020 and continuing to the date of this report to some degree. These factors may continue to adversely impact our revenue and capital resources, although the extent and duration of that impact is currently uncertain. (Please refer to “Special Note Regarding Forward-Looking Statements and Projections” above.)

30

In response to these developments, we have implemented measures to mitigate the impact of the pandemic on our financial position and operations. These measures include the following:

•We are continuing to monitor the effects of the SARS-CoV-2 variants and to increase our engagement with our customers to mitigate any anticipated loss of revenue in those markets that may be affected.

•We are investing in e-marketing and in enhancing our capabilities to conduct meetings virtually as well as in person.

For more information about the effect of the COVID-19 pandemic on our business and the related risks we face, please see Part I, Item 1A, “Risk Factors – Risks Related to the Public Health Pandemic,” in the 2021 Form 10-K.

Transactions with Ocumension Therapeutics

On April 14, 2021, we entered into a transaction with Ocumension Therapeutics, incorporated in the Cayman Islands with limited liability (Ocumension), or one of its affiliates. In the Ocumension transaction, we received a total of $20.0 million in cash under two agreements:

•a Share Purchase Agreement with Ocumension, pursuant to which we offered and sold to Ocumension 1,144,945 shares of our common stock at a purchase price of $8.734044 per share, or $10.0 million in total; and

•an Exclusive License Agreement (the Ocumension License Agreement) with a wholly owned subsidiary of Ocumension, pursuant to which we granted an exclusive license for the development and commercialization of our 190 microgram fluocinolone acetonide intravitreal implant in applicator under Ocumension’s own branded label in China, East Asia, and the Western Pacific, in exchange for a nonrefundable upfront payment of $10.0 million and aggregated potential sales milestone payments of up to $89.0 million upon achievement by the Ocumension subsidiary of specified amounts of net sales of the licensed product in in the future. We recognized $11.0 million in license revenue from the Ocumension transaction (including the value of a warrant subscription agreement, which we received as consideration, to purchase 1,000,000 shares of Ocumension Therapeutics during a period of four years), in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers, with the remaining approximate $300,000 in consideration received classified as deferred revenue that will be recognized over the remaining term of the license agreement once Ocumension begins to sell products. Revenue from the Ocumension License Agreement is included within net revenue in the accompanying condensed consolidated statements of operations.

For more information about the Ocumension transaction, see Notes 9 and 16 of our notes to the accompanying Interim Condensed Consolidated Financial Statements (Interim Financial Statements) and our Current Report on Form 8-K filed with the SEC on April 14, 2021.

Sources of Revenues

Our revenues for the three months ended March 31, 2022 and 2021 were generated from product sales primarily in the U.S., Germany and the U.K. In the U.S., two large pharmaceutical distributors accounted for 58% and 50% of our consolidated product revenues for the three months ended March 31, 2022 and 2021, respectively. These U.S.-based distributors purchase ILUVIEN from us, maintain inventories of ILUVIEN and sell downstream to physician offices, pharmacies and hospitals. Internationally, in countries where we sell direct, our customers are hospitals, clinics and pharmacies. We sometimes refer to physician offices, pharmacies, hospitals and clinics as end users. In international countries where we sell to distributors, these distributors maintain inventory levels of ILUVIEN for sale to their customers.

License Agreement with EyePoint Pharmaceuticals US, Inc.

Under the July 2017 New Collaboration Agreement with EyePoint Pharmaceuticals US, Inc. (EyePoint), we have rights to the technology underlying ILUVIEN for the treatment of (a) human eye diseases, including uveitis, in Europe, the Middle East, and Africa, and (b) human eye diseases other than uveitis worldwide. During each of the three months ended March 31, 2022 and 2021, our net royalty expense payable to EyePoint was 5.2%. We will pay an additional 2% royalty on future global net revenues and other related consideration in excess of $75,000,000 in any year. (For more information about our agreement with EyePoint, including how we calculate the royalty percentages we are required to pay, see Note 9 of our notes to the accompanying Interim Financial Statements.)

‎

31

Results of Operations

	Three Months Ended
	March 31,
	2022		2021
	(In thousands, except share and per share data)
REVENUE:
PRODUCT REVENUE, NET	$	11,898	$	11,214
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION		(1,680)		(1,562)
GROSS PROFIT		10,218		9,652
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES		3,583		3,213
GENERAL AND ADMINISTRATIVE EXPENSES		3,240		3,413
SALES AND MARKETING EXPENSES		6,853		4,818
DEPRECIATION AND AMORTIZATION		689		638
OPERATING EXPENSES		14,365		12,082
LOSS FROM OPERATIONS		(4,147)		(2,430)
INTEREST EXPENSE AND OTHER		(1,364)		(1,343)
UNREALIZED FOREIGN CURRENCY GAIN, NET		108		125
CHANGE IN FAIR VALUE OF WARRANT ASSET		(552)		—
NET LOSS	$	(5,955)	$	(3,648)
NET LOSS PER SHARE — Basic and diluted	$	(0.85)	$	(0.63)
WEIGHTED AVERAGE SHARES OUTSTANDING — Basic and Diluted		6,990,737		5,755,424

Net Revenue

We generate revenue from ILUVIEN, our only product. In addition to generating revenue from product sales, we seek to generate revenue from other sources such as upfront fees, milestone payments in connection with collaborative or strategic relationships, and royalties resulting from the licensing of ILUVIEN or any future product candidates and other intellectual property. Revenue from our international distributors fluctuates depending on the timing of the shipment of ILUVIEN to the distributors and the distributors’ sales of ILUVIEN to their customers.

Net revenue increased by approximately $700,000, or 6%, to approximately $11.9 million for the three months ended March 31, 2022, compared to approximately $11.2 million for the three months ended March 31, 2021. The increase was related to increased demand in the U.S., along with increased sales to our international distributors offset by decreases driven by continued COVID-19 lockdowns in certain international markets.

Cost of Goods Sold, Excluding Depreciation and Amortization, and Gross Profit

Gross profit is affected by costs of goods sold, which includes costs of manufactured goods sold and royalty payments to EyePoint under the New Collaboration Agreement. Additionally, cost of goods sold by our international distributors fluctuates depending on the revenue share attributable to the respective contract.

Cost of goods sold, excluding depreciation and amortization, increased by approximately $100,000, or 6%, to approximately $1.7 million for the three months ended March 31, 2022, compared to approximately $1.6 million for the three months ended March 31, 2021. The increase was primarily related to our increased product sales.

Gross profit increased by approximately $500,000, or 5%, to approximately $10.2 million for the three months ended March 31, 2022, compared to approximately $9.7 million for the three months ended March 31, 2021. Gross margin was 86% for both the three months ended March 31, 2022 and 2021.

Research, Development and Medical Affairs Expenses

Currently, our research, development and medical affairs expenses are primarily focused on activities that support ILUVIEN and include salaries and related expenses for research and development and medical affairs personnel, including medical science liaisons. Our research, development and medical affairs expenses also include costs related to clinical studies such as the NEW DAY Study and the provision of medical affairs support, including symposia development for physician education, and costs related to compliance with FDA, EEA or other regulatory requirements. We expense both internal and external research and development costs as they are incurred.

32

Research, development and medical affairs expenses increased by approximately $400,000, or 13%, to approximately $3.6 million for the three months ended March 31, 2022, compared to approximately $3.2 million for the three months ended March 31, 2021. The increase was primarily attributable to increases of approximately $250,000 of scientific communication costs and $130,000 in consultant costs.

General and Administrative Expenses

General and administrative expenses consist primarily of compensation for employees in executive and administrative functions, including finance, accounting, legal, information technology, training and employee development. Other significant costs include facilities costs and professional fees for accounting and legal services, including legal services associated with obtaining and maintaining patents and managing license agreements. We expect to continue to incur significant costs to comply with the corporate governance, internal control and similar requirements applicable to public companies.

General and administrative expenses decreased by approximately $200,000, or 6%, to approximately $3.2 million for the three months ended March 31, 2022, compared to approximately $3.4 million for the three months ended March 31, 2021. The decrease was primarily attributable to a decrease in personnel costs.

Sales and Marketing Expenses

Sales and marketing expenses consist primarily of third-party service fees and compensation for employees for the commercial promotion of, the assessment of the commercial opportunity of, the development of market awareness for, the pursuit of reimbursement approval for, and the commercialization of ILUVIEN, including launch plans for ILUVIEN in new markets. Other costs include professional fees associated with developing plans for ILUVIEN or any future products or product candidates and maintaining public relations.

Sales and marketing expenses increased by approximately $2.1 million, or 44%, to approximately $6.9 million for the three months ended March 31, 2022, compared to approximately $4.8 million for the three months ended March 31, 2021. The increase was primarily attributable to increases of (a) approximately $950,000 in marketing costs, including costs for targeted health care providers and patient brand awareness campaigns; (b) approximately $770,000 of personnel costs, including commissions, and travel expenses; and (c) approximately $140,000 in market access costs.

Operating Expenses

As a result of the increases in various expenses described above, total operating expenses increased by approximately $2.3 million, or 19%, to approximately $14.4 million for the three months ended March 31, 2022, compared to approximately $12.1 million for the three months ended March 31, 2021. The increase was primarily attributable to increases of approximately $2.1 million in sales and marketing expenses and $200,000 in research, development and medical affairs expenses. These increases were offset by a decrease of approximately $200,000 in general and administrative expenses as described above.

Interest Expense and Other

Interest Expense and Other increased by approximately $100,000, or 8%, to approximately $1.4 million for the three months ended March 31, 2022, compared to approximately $1.3 million for the three months ended March 31, 2021.

Basic and Diluted Net Loss Applicable to Common Stockholders per Share of Common Stock

We follow FASB Accounting Standards Codification, Earnings Per Share (ASC 260), which requires the reporting of both basic and diluted earnings per share. Because our preferred stockholders participate in dividends equally with common stockholders (if we were to declare and pay dividends), we use the two-class method to calculate EPS. However, our preferred stockholders are not contractually obligated to share in losses.

Basic EPS is computed by dividing net loss available to stockholders by the weighted average number of shares outstanding for the period. Diluted EPS is calculated in accordance with ASC 260 by adjusting weighted average shares outstanding for the dilutive effect of common stock options, restricted stock units and warrants. In periods where a net loss is recorded, no effect is given to potentially dilutive securities, because the effect would be anti-dilutive.

Common stock equivalent securities that would potentially dilute basic EPS in the future but were not included in the computation of diluted EPS because they were either classified as participating and do not share in losses or would have been anti-dilutive, were approximately 1,916,665 for the three months ended March 31, 2022, and 1,715,210 for the three months ended March 31, 2021.

33

Results of Operations - Segment Review

The following selected unaudited financial and operating data are derived from our Interim Financial Statements. The results and discussions that follow reflect how executive management monitors the performance of our reporting segments.

Our U.S. and International segments represent the sales and marketing, general and administrative and research and development activities dedicated to the respective geographies. The Operating Cost segment primarily represents the general and administrative and research and development activities not specifically associated with the U.S. or International segments and includes expenses such as executive management; information technology administration and support; legal; compliance; clinical studies; and business development. In monitoring performance, aligning strategies and allocating resources, our CODM manages and evaluates our U.S., International and Operating Cost segments based on segment income or loss from operations adjusted for certain non-cash items, such as stock-based compensation expense and depreciation and amortization. Therefore, we classify within Other (a) the non-cash expenses included in research, development and medical affairs expenses; general and administrative expenses; and sales and marketing expenses; and (b) depreciation and amortization.

Each of our U.S., International and Operating Cost segments is separately managed and is evaluated primarily upon segment income or loss from operations. Other is presented to reconcile to our consolidated totals. For that reconciliation, please see Note 19 of the accompanying consolidated financial statements. We do not report balance sheet information by segment because our CODM does not review that information. We allocate certain operating expenses among our reporting segments based on activity-based costing methods. These activity-based costing methods require us to make estimates that affect the amount of each expense category that is attributed to each segment. Changes in these estimates will directly affect the amount of expense allocated to each segment and therefore the operating profit of each reporting segment.

U.S. Segment

	Three Months Ended
	March 31,
	2022		2021
	(In thousands)
REVENUE:
PRODUCT REVENUE, NET	$	6,919	$	5,647
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION		(815)		(751)
GROSS PROFIT		6,104		4,896
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES		1,170		725
GENERAL AND ADMINISTRATIVE EXPENSES		317		241
SALES AND MARKETING EXPENSES		4,674		3,278
OPERATING EXPENSES		6,161		4,244
SEGMENT (LOSS) INCOME FROM OPERATIONS	$	(57)	$	652

U.S. Segment - three months ended March 31, 2022 compared to the three months ended March 31, 2021

Net revenue. Net revenue increased by approximately $1.3 million, or 23%, to approximately $6.9 million for the three months ended March 31, 2022, compared to approximately $5.6 million for the three months ended March 31, 2021. The U.S. market saw continued growth driven by our targeted programs to support physician reengagement.

Cost of goods sold, excluding depreciation and amortization. Cost of goods sold, excluding depreciation and amortization, increased by approximately $70,000, or 9%, to approximately $820,000 for the three months ended March 31, 2022, compared to approximately $750,000 for the three months ended March 31, 2021. The increase was primarily attributable to our increased product sales.

Research, development and medical affairs expenses. Research, development and medical affairs expenses increased by approximately $470,000, or 64%, to approximately $1.2 million for the three months ended March 31, 2022, compared to approximately $730,000 for the three months ended March 31, 2021. The increase was primarily attributable to increases of approximately $240,000 in scientific communication costs and $190,000 in personnel costs.

General and administrative expenses. General and administrative expenses increased by approximately $80,000, or 33%, to approximately $320,000 for the three months ended March 31, 2022, compared to approximately $240,000 for the three months ended March 31, 2021.

34

Sales and marketing expenses. Sales and marketing expenses increased by approximately $1.3 million, or 39%, to approximately $4.6 million for the three months ended March 31, 2022, compared to approximately $3.3 million for the three months ended March 31, 2021. The increase was primarily attributable to increases of approximately $740,000 in marketing costs, including costs for targeted health care providers and patient brand awareness campaigns and $590,000 in personnel costs including increased commissions and travel expenses.

International Segment

	Three Months Ended
	March 31,
	2022		2021
	(In thousands)
REVENUE:
PRODUCT REVENUE, NET	$	4,979	$	5,567
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION		(865)		(811)
GROSS PROFIT		4,114		4,756
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES		916		941
GENERAL AND ADMINISTRATIVE EXPENSES		422		587
SALES AND MARKETING EXPENSES		2,004		1,334
OPERATING EXPENSES		3,342		2,862
SEGMENT INCOME FROM OPERATIONS	$	772	$	1,894

International Segment - three months ended March 31, 2022 compared to the three months ended March 31, 2021

Net revenue. Net revenue decreased by approximately $600,000, or 11%, to approximately $5.0 million for the three months ended March 31, 2022, compared to approximately $5.6 million for the three months ended March 31, 2021. The decrease was driven by continued COVID-19 lockdowns in our international markets. The U.K. came out of lockdown in late January, while Germany came out of lockdown near the end of March.

Cost of goods sold, excluding depreciation and amortization. Cost of goods sold, excluding depreciation and amortization, increased by approximately $60,000, or 7%, to approximately $870,000 for the three months ended March 30, 2022, compared to approximately $810,000 for the three months ended March 31, 2021. The increase was mainly due to the mix of products sold to international distributors and to customers in our direct markets. Cost of goods sold is generally a higher percentage of net revenue for our international distributors than for our international direct customers.

Research, development and medical affairs expenses. Research, development and medical affairs expenses decreased by approximately $20,000, or 2%, to approximately $920,000 for the three months ended March 31, 2022, compared to approximately $940,000 for the three months ended March 31, 2021.

General and administrative expenses. General and administrative expenses decreased by approximately $170,000, or 29%, to approximately $420,000 for the three months ended March 31, 2022, compared to approximately $590,000 for the three months ended March 31, 2021. The decrease was primarily attributable to a decrease in personnel costs.

Sales and marketing expenses. Sales and marketing expenses increased by approximately $700,000, or 54%, to approximately $2.0 million for the three months ended March 31, 2022, compared to approximately $1.3 million for the three months ended March 31, 2021. The increase was primarily attributable to increases of (a) approximately $230,000 in personnel costs; (b) approximately $210,000 in marketing costs; and (c) approximately $140,000 in market access costs.

35

Operating Cost Segment

	Three Months Ended
	March 31,
	2022			2021
	(In thousands)
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES	$	1,461	$	$	1,538
GENERAL AND ADMINISTRATIVE EXPENSES		2,283			2,396
SALES AND MARKETING EXPENSES		117			143
OPERATING EXPENSES		3,861			4,077
SEGMENT LOSS FROM OPERATIONS	$	(3,861)		$	(4,077)

Operating Cost Segment - three months ended March 31, 2022 compared to the three months ended March 31, 2021

Research, development and medical affairs expenses. Research, development and medical affairs expenses was approximately $1.5 million for each of the three months ended March 31, 2022 and 2021.

General and administrative expenses. General and administrative expenses increased by approximately $100,000, or 4%, to approximately $2.3 million for the three months ended March 31, 2022, compared to approximately $2.4 million for the three months ended March 31, 2021.

Sales and marketing expenses. Sales and marketing expenses decreased by approximately $20,000, or 14%, to approximately $120,000 for the three months ended March 31, 2022, compared to approximately $140,000 for the three months ended March 31, 2021.

Other

	Three Months Ended
	March 31,
	2022		2021
	(In thousands)
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES	$	36	$	9
GENERAL AND ADMINISTRATIVE EXPENSES		218		189
SALES AND MARKETING EXPENSES		58		63
DEPRECIATION AND AMORTIZATION		689		638
OPERATING EXPENSES		1,001		899
OTHER LOSS FROM OPERATIONS	$	(1,001)	$	(899)

Our CEO, who is our chief operating decision maker, manages and evaluates our U.S., International and Operating Cost segments based upon segment income or loss from operations adjusted for certain non-cash items, such as stock-based compensation expense and depreciation and amortization. We classify the non-cash expenses included in research, development and medical affairs expenses, general and administrative expenses, and sales and marketing expenses within Other in our Interim Financial Statements.

Operating expenses. Operating expenses in Other increased by approximately $100,000, or 11%, to $1.0 million for the three months ended March 31, 2022, compared to approximately $900,000 for the three months ended March 31, 2021. This increase was primarily attributable to an increase in global stock-based compensation expenses.

Depreciation and amortization. Depreciation and amortization was approximately $690,000 and $640,000 for the three months ended March 31, 2022 and 2021, respectively.

Liquidity and Capital Resources

Overview

Since inception, we have incurred recurring losses, negative cash flow from operations and have accumulated a deficit in stockholders’ equity of $403.2 million as of March 31, 2022. As of March 31, 2022, we had approximately $9.9 million in cash and cash equivalents. In mid-April 2021 we received a total of $20.0 million in cash from the Ocumension transaction described above. We have used and are using these funds to continue to commercialize ILUVIEN, to fund our NEW DAY clinical trial and for general corporate purposes, which may include working capital, capital expenditures, other clinical trial expenditures, acquisitions of new technologies, products or businesses in ophthalmology, and investments.

36

As explained above in “Effects of the COVID-19 Pandemic,” the unprecedented events of the COVID-19 pandemic, and its unpredictable duration, in the regions where we have customers, employees and distributors have had an adverse effect on our sales of ILUVIEN and thus on our net revenues and capital resources. The extent and duration of that impact is uncertain at this time, particularly in light of the emergence of COVID-19 variants that increase the transmissibility of the coronavirus.

Since January 2020, we have funded our operations through:

(a)cash received from our sales;

(b)net proceeds of the loans that we obtained in December 2019 and February 2020 from a group of lenders led by SLR Investment Corp. (formerly named Solar Capital Ltd.) under a $45.0 million loan and security agreement (the 2019 Loan Agreement);

(c)an approximately $1.8 million loan (the PPP Loan) we obtained in April 2020 under the Paycheck Protection Program established as part of the Coronavirus Aid, Relief and Economic Security Act, or the CARES Act, which was forgiven in its entirety, including interest, on April 16, 2021; and

(d)the $20.0 million in funds we obtained in April 2021 as a result of the Ocumension transaction.

The 2019 Loan Agreement does not include a revolving loan feature and has been fully advanced by the lenders. We currently have no additional borrowing capacity, and the 2019 Loan Agreement generally prohibits any additional debt unless we obtain the prior consent of the lenders.

Indebtedness

Loans from SLR Investment Corp. (SLR, formerly known as Solar Capital Ltd. until February 2021). On January 5, 2018, we entered into a $40.0 million loan and security agreement with SLR, as Collateral Agent, and the parties signatory thereto from time to time as Lenders, including SLR in its capacity as a lender (the 2018 Loan Agreement). On December 31, 2019, we refinanced the 2018 Loan Agreement by entering into a $45.0 million loan and security agreement (the 2019 Loan Agreement) with SLR, as the Collateral Agent, and the parties signing the loan agreement from time to time as Lenders, including SLR in its capacity as a Lender (collectively, the Lenders). Under the 2019 Loan Agreement, we borrowed $42.5 million on December 31, 2019 and borrowed the remaining $2.5 million on February 21, 2020. The two borrowings under the 2019 Loan Agreement totaled $45.0 million and are referred to as the SLR Loan. The SLR Loan matures on July 1, 2024. We used the initial proceeds of the SLR Loan to pay off the outstanding loan under the 2018 Loan Agreement, along with related prepayment, legal and other fees and expenses totaling approximately $2.3 million, which included $2.2 million in fees to SLR. We used the remaining proceeds of the SLR Loan to provide additional working capital for general corporate purposes during 2020 and the first half of 2021.

On May 1, 2020, we entered into a First Amendment to the 2019 Loan Agreement (the First Amendment). The First Amendment included revised covenants that applied to our financial performance during 2020, all of which we met. The First Amendment, among other things, required that a minimum revenue covenant be measured at March 31, 2021 and at the last day of each quarter thereafter, with the minimum revenue amount equal to a percentage of our projected revenues in accordance with a plan we submitted to the Collateral Agent in February 2021, with such plan to be approved by our board of directors (the Board) and the Collateral Agent in its sole discretion.

On March 30, 2021, we entered into a Second Amendment to the 2019 Loan Agreement (the Second Amendment), which among other things:

(a)reflected the Collateral Agent’s consent to our delivery of Board-approved annual financial projections for 2021 by April 1, 2021 (which we delivered in a timely manner);

(b)specified the minimum revenue amount, calculated on a trailing six-month basis and tested at the end of each calendar quarter in 2021, that we must achieve for each such period (the Revenue Covenant);

(c)required that the Revenue Covenant be tested at March 31, 2022 and at the last day of each quarter thereafter, with the minimum revenue amount equal to a percentage of our projected revenues in accordance with an annual plan we must submit to the Collateral Agent by January 15th of such year, such plan to be approved by our Board and the Collateral Agent in its sole discretion; and

(d)provided that in future years we must deliver to the Collateral Agent and the Lenders as soon as available after approval thereof by our Board, but no later than the earlier of (x) 15 days after such approval and (y) February 28 of such year, our annual financial

37

projections for the entire current fiscal year as approved by our Board, provided that any revisions to such projections approved by our Board shall be delivered to the Collateral Agent and the Lenders no later than seven days after such approval.

On February 22, 2022, we entered into a Third Amendment to the 2019 Loan Agreement (the Third Amendment), which, among other things:

(a)specified the minimum revenue amount, calculated on a trailing six-month basis and tested at the end of each calendar quarter in 2022, that we must achieve for each such period (the Revenue Covenant);

(b)consented to maintaining a lower minimum revenue amount under the Revenue Covenant for the trailing six-month period ended December 31, 2021 than previously required under the 2019 Loan Agreement (and waived any event of default that may have occurred or may be deemed to have occurred as a result of our lower revenue amount for that period); and

(c)required that the Revenue Covenant be tested at March 31, 2023 and at the last day of each quarter thereafter, with the minimum revenue amount equal to a percentage of our projected revenues in accordance with an annual plan we must submit to the Collateral Agent by January 15 of such year, such plan to be thereafter approved by our Board and the Collateral Agent in its sole discretion no later than February 28 of such year.

Interest on the 2019 Loan Agreement is payable at the greater of (i) one-month LIBOR or (ii) 1.78%, in either case plus 7.65% per annum. As of March 31, 2022, the interest rate under the 2019 Loan Agreement was 9.43%. The 2019 Loan Agreement provides for interest only payments until January 1, 2023. If we meet certain revenue thresholds and no event of default shall have occurred and is continuing, we can extend the interest only period an additional six months, ending on June 30, 2023, followed by one year of monthly payments of principal and interest.

The Federal Reserve recently raised interest rates to combat the effects of inflation and has announced that it expects to continue to do so in the future. An increase in LIBOR (or a successor interest rate) would increase our interest costs. For example, a 1.0% increase in the interest rate under the 2019 Loan Agreement above the interest rate that applied to us as of March 31, 2022 (9.43%) would increase our interest expense by approximately $444,000 per year and reduce our liquidity and capital resources by that amount. A more significant increase could materially and adversely affect our results of operations and our ability to pay amounts due under the 2019 Loan Agreement.

Our operations and thus our net product revenues have continued to be adversely affected by the COVID-19 pandemic. During each of the six months ended September 30, 2021 and December 31, 2021, we did not generate sufficient revenue to meet the trailing six-month Revenue Covenant included in the 2019 Loan Agreement. For each such six-month period, the Lenders provided a consent that permitted us not to maintain the Revenue Covenant as of September 30, 2021 and December 31, 2021, respectively, and waived any event of default that may have occurred or may have been deemed to have occurred. We were in compliance with the Revenue Covenant as of March 31, 2022 and expect to comply with the Revenue Covenant at the next reportable date, which is June 30, 2022, and through one year after the filing date of this Quarterly Report on Form 10-Q, although we can give no assurances in that regard. However, due to the remaining uncertainty surrounding the COVID-19 pandemic, it is possible that we will fail to comply with the Revenue Covenant. If we fail to comply with the Revenue Covenant and the Lenders do not provide a consent and waiver, acceleration of the maturity of the loan is one of the remedies available to the Lenders. If the Lenders accelerate the maturity of the loan, we would be forced to find alternative financing or enter into an alternative agreement with the Lenders. We cannot be sure that alternative financing will be available when needed or that, if available, the alternative financing could be obtained on terms that are not significantly detrimental to us or our stockholders. See the risk factor related to the 2019 Loan Agreement in Part I, Item 1A of the 2021 Form 10-K.

Paycheck Protection Program Loan. On April 22, 2020, we received an approximately $1.8 million loan (the PPP Loan) under the Paycheck Protection Program established by the U.S. Small Business Administration as part of the Coronavirus Aid, Relief and Economic Security Act, or the CARES Act. The PPP Loan was unsecured and was evidenced by a note in favor of HSBC Bank USA, National Association (HSBC) as the lender. On July 21, 2020, we submitted an application to HSBC for forgiveness of the PPP Loan. The PPP Loan was forgiven in its entirety, including interest, on April 16, 2021.

$20.0 million Capital Infusion from Ocumension

On April 14, 2021, we entered into a Share Purchase Agreement with Ocumension Therapeutics, pursuant to which we offered and sold to Ocumension 1,144,945 shares of our common stock, at a purchase price of $8.734044 per share. The number of shares sold was equal to 19.9% of the number of shares of common stock outstanding immediately before the closing. The aggregate gross proceeds from the sale of the shares were $10.0 million. In addition, we received a nonrefundable upfront license payment of $10.0 million pursuant to the Ocumension License Agreement. For more information about the Ocumension transaction, see “Transactions with Ocumension

38

Therapeutics” above, Notes 9 and 16 of our notes to the accompanying Interim Financial Statements, and our Current Report on Form 8-K filed with the SEC on April 14, 2021.

Current Cash Position

As of March 31, 2022, we had approximately $9.9 million in cash and cash equivalents, a decrease of $6.6 million from the $16.5 million in cash and cash equivalents that we reported as of December 31, 2021.

In April 2021, we received gross proceeds of $20.0 million in cash from the Ocumension transaction described above. As we have previously disclosed, we have used some of these proceeds to invest in targeted spending programs in both the U.S. and international markets to drive reengagement with physicians and accelerate our growth. While we believe many of these investments have proven to be successful, we also realize that continuing to spend at those levels in certain markets is not sustainable without the offsetting higher revenues we hoped to achieve. To conserve our cash, we are curtailing some of our spending in our international markets to address the slower than expected revenue growth in Europe coming out of the pandemic, and we expect to continue to monitor our ongoing spending programs closely.

We may need to raise additional capital to fund our business strategy, including the continued commercialization of ILUVIEN and the retention and in certain areas, the expansion, of our current employees and staff. The actual amount of funds that we may need will depend on many factors, some of which are beyond our control. See Part I, Item 1, “Business - The COVID-19 Pandemic and Our Steps to Address its Effects on Our Business” of the 2021 Form 10-K for an explanation of how we are seeking to mitigate the impact of the pandemic on our financial position and operations.

We cannot be sure that additional financing will be available when needed or that, if available, the additional financing could be obtained on terms that are not significantly detrimental to us or our stockholders. If we were to raise additional funds by issuing equity securities, substantial dilution to existing stockholders could result, and the terms of any new equity securities may have a preference over our common stock. If we were to attempt to raise additional funds through strategic collaboration agreements, we may not be successful in obtaining those agreements, or in receiving milestone or royalty payments under them. If we were to attempt to raise additional funds through debt financing, we would be required to obtain the permission or participation of SLR, which we might not be able to obtain. Our recurring losses and any potential needs to raise capital create substantial doubt about our ability to continue as a going concern for the next 12 months following the issuance of the financial statements for the filing of this Quarterly Report on Form 10-Q.

Sources and Uses of Cash for the three months ended March 31, 2022 compared to the three months ended March 31, 2021

For the three months ended March 31, 2022, net cash used in our operations was approximately $6.2 million. The cash used in our operations was impacted by our net loss of approximately $6.0 million and a net decrease of $2.5 million in accounts payable, accrued expenses and other current liabilities. Cash used in operations for the three months ended March 31, 2022 was offset by $690,000 of non-cash depreciation and amortization, a $550,000 decrease in fair value of our warrant asset, $310,000 of non-cash stock-based compensation expense, $270,000 of non-cash interest expense associated with the amortization of our debt discount and deferred financing costs, a decrease of $270,000 in prepaid expenses and other current assets, a decrease of $200,000 in inventory and a decrease of $180,000 in accounts receivable.

For the three months ended March 31, 2021, net cash used in our operations was approximately $2.5 million. The cash used in our operations was primarily due to our net loss of $3.6 million and a decrease of $1.3 million in accounts payable, accrued expenses and other current liabilities. Cash used in operations for the three months ended March 31, 2021 was offset by a decrease in accounts receivable of $1.3 million, $640,000 of non-cash depreciation and amortization, $260,000 of non-cash stock-based compensation expense, $240,000 of non-cash interest expense associated with the amortization of our debt discount and a $110,000 decrease in inventory.

For the three months ended March 31, 2022, net cash used in our investing activities was approximately $150,000, which was primarily due to purchases of furniture for our new U.S. headquarters.

For the three months ended March 31, 2021, net cash used in our investing activities was approximately $80,000, which was primarily due to capital expenditures associated with the transfer of manufacturing to Cadence, Inc.

For the three months ended March 31, 2022, net cash used in our financing activities was approximately $60,000, which was primarily due to payments of finance lease obligations.

39

For the three months ended March 31, 2021, net cash used in our financing activities was approximately $60,000, which was primarily due to payments of finance lease obligations.

Contractual Obligations and Commitments

2019 Loan Agreement. The outstanding loan under the 2019 Loan Agreement (the SLR Loan) provides for interest only payments until January 1, 2023, followed by 19 monthly payments of principal and interest until the SLR Loan matures on July 1, 2024. We estimate that we will be obligated to pay to the Lenders $45.0 million in loan principal and approximately $6.5 million in interest through July 1, 2024 at the current rate of 9.43% per annum (which may be higher as noted above).

The NEW DAY Study. In January 2020, we began entering into agreements with contract research organizations (CROs) and physician clinics in connection with a multicenter, single masked, randomized and controlled trial designed to generate prospective data evaluating ILUVIEN as a baseline therapy in the treatment of DME and demonstrate its advantages over the current standard of care of repeat anti-VEGF injections (the NEW DAY Study). The NEW DAY Study is planned to enroll approximately 300 treatment-naïve, or almost naïve, DME patients in approximately 42 sites around the U.S. For the three months ended March 31, 2022 and March 31, 2021, we incurred approximately $960,000 and $890,000, respectively, of expense associated with the NEW DAY Study. In connection with the NEW DAY Study, we expect to incur additional expenses of approximately $5.1 million for the remainder of 2022, $5.5 million in 2023 and $1.0 million in 2024.

Manufacturing Services Agreement with Alliance. In February 2016, we and Alliance Medical Products Inc., a Siegfried Company (Alliance), a third-party manufacturer, amended and restated the parties’ existing agreement for the manufacture of the ILUVIEN implant, the assembly of the ILUVIEN applicator and the packaging of the completed ILUVIEN commercial product. Under the amended and restated Alliance agreement, its term was extended by five years, at which point the agreement became automatically renewable for successive one-year periods unless either party delivers notice of non-renewal to the other party at least 12 months before the end of the term or any renewal term. We are responsible for supplying the ILUVIEN applicator and the active pharmaceutical ingredient, and we must order at least 80% of the ILUVIEN units required in the U.S., Canada and the EEA from Alliance.

Manufacturing Services Agreement with Cadence. On October 30, 2020, we entered into a Manufacturing Services Agreement (the Cadence Agreement) with Cadence, Inc., for the manufacture of certain component parts of the ILUVIEN applicator (the components) at its facility near Pittsburgh, Pennsylvania. Under the Cadence Agreement, we will pay certain per-unit prices based on regularly scheduled shipments of a minimum number of components. The initial term of the Cadence Agreement expires on October 30, 2025. After the expiration of the initial term, the Cadence Agreement will automatically renew for separate but successive one-year terms unless either party provides written notice to the other party that it does not intend to renew the Cadence Agreement at least 24 months before the end of the term. The Cadence Agreement may be terminated by either party under certain circumstances. To date, we have been in the process of transferring the manufacturing of parts to Cadence and have spent cash resources to purchase new equipment, to update clean room facilities and to assist in the regulatory approval process. In connection with the Cadence Agreement, we expect to be invoiced approximately $650,000 in each of 2022 and 2023.

Off-Balance Sheet Arrangements

We do not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, that would have been established to facilitate off-balance sheet arrangements (as that term is defined in Item 303(a)(4)(ii) of SEC Regulation S-K) or other contractually narrow or limited purposes. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in those types of relationships. We enter into guarantees in the ordinary course of business related to the guarantee of our own performance and the performance of our subsidiaries.

Impact of Recent Accounting Pronouncements

See Note 3 of our notes to Interim Financial Statements for a description of recent accounting pronouncements, including the expected dates of adoption and expected effects on results of operations and financial condition, if known.

‎

40

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk

Not required for smaller reporting companies.

ITEM 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including the Chief Executive Officer and the Chief Financial Officer, we evaluated the effectiveness of the design and operation of our “disclosure controls and procedures” (as defined in Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2022.

Changes in Internal Control over Financial Reporting

There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the three months ended March 31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Limitations on the Effectiveness of Controls

Control systems, no matter how well conceived and operated, are designed to provide a reasonable, but not an absolute, level of assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. Because of the inherent limitations in any control system, misstatements due to error or fraud may occur and not be detected.

‎

41

PART II. OTHER INFORMATION

ITEM 1. Legal Proceedings

We are not a party to any material pending legal proceedings, and management is not aware of any contemplated proceedings by any governmental authority against us.

ITEM 1A. Risk Factors

In the 2021 Form 10-K, we identify under Item 1A of Part I important factors that could affect our business, financial condition, results of operations and future operations and could cause our actual results for future periods to differ materially from our anticipated results or other expectations, including those expressed in any forward-looking statements made in this Quarterly Report on Form 10-Q. There have been no material changes in our risk factors since the filing of the 2021 Form 10-K. However, the risks described in the 2021 Form 10-K are not the only risks we face. Additional risks and uncertainties that we currently deem to be immaterial or not currently known to us, as well as other risks reported from time to time in our reports to the SEC, also could cause our actual results to differ materially from our anticipated results or other expectations.

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

ITEM 3. Defaults Upon Senior Securities

None.

ITEM 4. Mine Safety Disclosures

Not applicable.

ITEM 5. Other Information

None.

 
‎

42

ITEM 6. Exhibits

Exhibit Number	Description
3.1	Restated Certificate of Incorporation of Registrant, as amended on various dates (filed as Exhibit 3.1 to the Registrant’s Annual Report on Form 10-K, as filed on March 2, 2020, and incorporated herein by reference).
3.2	Amended and Restated Bylaws of the Registrant, as amended (filed as Exhibit 3.2 to the Registrant’s Annual Report on Form 10-K, as filed on March 2, 2020 and incorporated herein by reference).
10.11.G*#	Third Amendment to Loan and Security Agreement dated February 22, 2022, by and among Alimera Sciences, Inc., SLR Investment Corp., as Collateral Agent, and the parties signatory thereto as Lenders, including SLR in its capacity as a Lender.
31.1*	Certification of the Principal Executive Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of the Principal Financial Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certification of the Chief Executive Officer and Chief Financial Officer, as required by Section 906 of the Sarbanes-Oxley Act of 2002.
101	The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, formatted in Inline XBRL: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statements of Comprehensive Loss, (iv) Condensed Consolidated Statements of Cash Flows, (v) Condensed Consolidated Statements of Changes in Stockholders’ (Deficit) and (vi) Notes to Condensed Consolidated Financial Statements, tagged as blocks of text and including detailed tags.
104	Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit 101).

*Filed herewith.

#Certain confidential information contained in this agreement has been omitted because it is not material and would be competitively harmful if publicly disclosed.

The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Alimera Sciences, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing. 

‎

43

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ALIMERA SCIENCES, INC.
May 12, 2022	By:	/s/ Richard S. Eiswirth, Jr.
		Richard S. Eiswirth, Jr.
		President and Chief Executive Officer
		(Principal Executive Officer)
May 12, 2022	By:	/s/ J. Philip Jones
		J. Philip Jones
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

44

EX-10.11.G

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

Exhibit 10.11.G

THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT

THISTHIRD AMENDMENTTO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of February 22, 2022, by and among SLR Investment Corp., a Maryland corporation, (“SLR”), as collateral agent (in such capacity, together with its successors and assigns in such capacity, “Collateral Agent”), the lenders party hereto including SLR in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), and Alimera Sciences, Inc., a Delaware corporation (“Borrower”).

W I T N E S S E T H:

WHEREAS, Borrower, the Lenders, and Collateral Agent are parties to that certain Loan and Security Agreement, dated as of December 31, 2019 (as amended by the First Amendment to Loan and Security Agreement, dated as of May 1, 2020, by that certain Second Amendment to Loan and Security Agreement dated as of March 30, 2021, and as further amended, restated, supplemented or otherwise modified from time to time prior to the date hereof, the “Loan and Security Agreement”). 

WHEREAS,  Borrower has requested certain amendments to the Loan and Security Agreement as more fully set forth herein and Collateral Agent and the Lenders are willing to agree to such request, subject to and in accordance with the terms and conditions set forth in this Amendment.

NOW, THEREFORE, in consideration of the premises, covenants and agreements contained herein, and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Borrower, the Lenders, and Collateral Agent hereby agree as follows:

DEFINITIONS; Interpretation.

(a) Terms Defined in Loan and Security Agreement.  All capitalized terms used in this Amendment (including in the recitals hereof) and not otherwise defined herein shall have the meanings assigned to them in the Loan and Security Agreement.

(b) Interpretation.  The rules of interpretation set forth in Section 1.1 of the Loan and Security Agreement shall be applicable to this Amendment and are incorporated herein by this reference.

1. Consent. 

(c) In accordance with Section 12.5 of the Loan and Security Agreement and subject to the other terms and conditions set forth herein, Collateral Agent and the Lenders hereby consent, and Borrower hereby agrees, that notwithstanding the terms of Section 7.13 of the Loan and Security Agreement, Borrower shall be permitted to maintain a Minimum Revenue Amount for the measurement period ending on December 31, 2021 of less than the Minimum Revenue Amount otherwise required by Section 7.13 of the Loan and Security Agreement, and Lenders hereby waive any Event of Default that may have occurred, or may be deemed to have occurred, as a result of Borrower’s maintenance of a Minimum Revenue Amount that is less than the Minimum Revenue Amount required by Section 7.15 of the Loan and Security Agreement as of and for the measurement period ending on December 31, 2021.

(d) Collateral Agent’s and the Lenders’ consent and waiver under this Section 2 shall not limit or impair Collateral Agent’s or the Lenders’ right to demand strict performance of all other covenant(s) as of any date.

(e) The consent and waiver set forth in this Section 2 is effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (1) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (2) otherwise prejudice any

right or remedy which Collateral Agent or the Lenders may now have or may have in the future under or in connection with any Loan Document.

Amendments to loan and security agreement.

(f) The Loan and Security Agreement shall be amended as follows:

Section 7.13.  Section 7.13(a) of the Loan and Security Agreement is hereby amended and restated in its entirety as follows:

(a) Minimum Revenue Amount. Permit revenues (under GAAP) from the sale in the ordinary course of business to third party customers of ILUVIEN by Borrower, on a trailing six (6) month basis, tested at November 30, 2020 (the “Interim Revenue Testing Date”) for the trailing six (6) month period then ended and subsequently tested at the end of eachquarter thereafter, to be less than the applicable Minimum Revenue Amount set forth below for such testing date:

TestingDate:	Minimum Revenue Amount:
November 30, 2020	$[***]
December 31, 2020	$[***]
March 31, 2021	$[***]
June 30, 2021	$[***]
September 30, 2021	$[***]
December 31, 2021	$[***]
March 31, 2022	$[***]
June 30, 2022	$[***]
September 30, 2022	$[***]
December 31, 2022	$[***]
March 31, 2023 and the last day of each quarter thereafter	[***]% of projected revenues in accordance with an annual plan submitted by Borrower to Collateral Agent by January 15th of such year (i.e., January 15, 2023 for the 2023 quarterly covenants), such plan to be thereafter approved by Borrower’s board of directors and Collateral Agent in its sole discretion no later than February 28 of such year.

(g) References Within Loan and Security Agreement.  Each reference in the Loan and Security Agreement to “this Agreement” and the words “hereof,” “herein,” “hereunder,” or words of like import, shall mean and be a reference to the Loan and Security Agreement as amended by this Amendment.

CONDITIONS TO EFFECTIVENESS

.  This Amendment shall become effective upon satisfaction of each of the conditions specified below:

(h) This Amendment.  Collateral Agent shall have received one or more counterparts of this Amendment, duly executed, completed and delivered by Collateral Agent, each Lender and Borrower;

(i) Fees and Expenses.  Borrower shall have paid (i) all invoiced costs and expenses then due in accordance with Section 9, (ii) all other fees, costs and expenses, if any, due and payable as of the date of this Amendment under the Loan and Security Agreement,  and (iii) an amendment fee of $45,000 to the Collateral Agent for and on behalf of the Lenders (the “Amendment Fee”);

2

(j) Representations and Warranties; No Default.  As of the date of this Amendment, after giving effect to the amendment of the Loan and Security Agreement contemplated hereby:

(i) The representations and warranties contained in Section 4 of this Amendment shall be true and correct on and as of the date of this Amendment as though made on and as of such date; and

(ii) There exist no Default or Events of Default; and

(k) Collateral Agent shall have received all other documents and instruments as Collateral Agent or any Lender may reasonably deem necessary or appropriate to effectuate the intent and purpose of this Amendment.

For the avoidance of doubt, the Amendment Fee shall be fully earned on the date so paid, non-refundable for any reason and payable to the Lenders in accordance with their respective Pro Rata Shares.

REPRESENTATIONS AND WARRANTIES

.  To induce Collateral Agent and the Lenders to enter into this Amendment, Borrower hereby confirms, as of the date hereof, (a) that the representations and warranties made by it in Section 5 of the Loan and Security Agreement and in the other Loan Documents are true and correct in all material respects; provided,  however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof, provided, further, that to the extent such representations and warranties by their terms expressly relate only to a prior date such representations and warranties shall be true and correct as of such prior date; (b) that there has not been and there does not exist a Material Adverse Change; (c) reserved; (d) Collateral Agent and the Lenders have and shall continue to have valid, enforceable and perfected first-priority liens, subject only to Permitted Liens, on and security interests in the Collateral and all other collateral heretofore granted by Borrower to Collateral Agent and the Lenders pursuant to the Loan Documents or otherwise granted to or held by Collateral Agent and the Lenders; (e) the agreements and obligations of Borrower contained in the Loan Documents and in this Amendment constitute the legal, valid and binding obligations of Borrower, enforceable against Borrower in accordance with their respective terms, except as the enforceability thereof may be limited by bankruptcy, insolvency or other similar laws of general application affecting the enforcement of creditors’ rights or by the application of general principles of equity; and (f) the execution, delivery and performance of this Amendment by Borrower will not (i) conflict with Borrower’s organizational documents, including its Operating Documents, (ii) contravene, conflict with, constitute a default under or violate any material Requirement of Law applicable thereto, (iii)contravene, conflict or violate any applicable material order, writ, judgment, injunction, decree, determination or award of any Governmental Authority by which Borrower or any of its property or assets may be bound or affected, and (iv) constitute an event of default under any material agreement by which Borrower or any of its properties is bound, the termination or noncompliance with which could reasonably be expected to have a Material Adverse Change.  For the purposes of this Section, each reference in Section 5 of the Loan and Security Agreement to “this Agreement,” and the words “hereof,” “herein,” “hereunder,” or words of like import in such Section, shall mean and be a reference to the Loan and Security Agreement as amended by this Amendment.

LOAN DOCUMENTS OTHERWISE NOT AFFECTED; REAFFIRMATION; NO NOVATION

.

(l) Except as expressly amended pursuant hereto or referenced herein, the Loan and Security Agreement and the other Loan Documents shall remain unchanged and in full force and effect and are hereby ratified and confirmed in all respects.  The Lenders’ and Collateral Agent’s execution and delivery of, or acceptance of, this Amendment shall not be deemed to create a course of dealing or otherwise create any express or implied duty by any of them to provide any other or further amendments, consents or waivers in the future. 

(m) Borrower hereby expressly (1) reaffirms, ratifies and confirms its Obligations under the Loan and Security Agreement and the other Loan Documents, (2)reaffirms, ratifies and confirms the grant of security under Section 4 of the Loan and Security Agreement, (3) reaffirms that such grant of security in the Collateral secures all Obligations under the Loan and Security Agreement, and with effect from (and including) the date hereof, such grant of security in the Collateral: (x) remains in full force and effect

3

notwithstanding the consent and waiver expressly referenced herein; and (y) secures all Obligations under the Loan and Security Agreement, as amended by this Amendment, and the other Loan Documents, (4) agrees that this Amendment shall be a “Loan Document” under the Loan and Security Agreement, and (5) agrees that the Loan and Security Agreement and each other Loan Document shall remain in full force and effect following any action contemplated in connection herewith.

(n) This Amendment is not a novation and the terms and conditions of this Amendment shall be in addition to and supplemental to all terms and conditions set forth in the Loan Documents. Nothing in this Amendment is intended, or shall be construed, to constitute an accord and satisfaction of Borrower’s Obligations under or in connection with the Loan and Security Agreement and any other Loan Document or to modify, affect or impair the perfection or continuity of Collateral Agent’s security interest in, (for the ratable benefit of the Secured Parties) security titles to or other liens on any Collateral for the Obligations.

Conditions

.  For purposes of determining compliance with the conditions specified in Section 3, each Lender that has signed this Amendment shall be deemed to have consented to, approved or accepted or to be satisfied with, each document or other matter required thereunder to be consented to or approved by or acceptable or satisfactory to a Lender unless Collateral Agent shall have received notice from such Lender prior to date hereof specifying its objection thereto.

RELEASE

.  In consideration of the agreements of Collateral Agent and each Lender contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Borrower, on behalf of itself and its successors, assigns, and other legal representatives, hereby fully, absolutely, unconditionally and irrevocably releases, remises and forever discharges Collateral Agent and each Lender, and its successors and assigns, and its present and former shareholders, affiliates, subsidiaries, divisions, predecessors, directors, officers, attorneys, employees, agents and other representatives (Agent, Lenders and all such other persons being hereinafter referred to collectively as the “Releasees” and individually as a “Releasee”), of and from all demands, actions, causes of action, suits, covenants, contracts, controversies, agreements, promises, sums of money, accounts, bills, reckonings, damages and any and all other claims, counterclaims, defenses, rights of set-off, demands and liabilities whatsoever of every name and nature, known or unknown, suspected or unsuspected, both at law and in equity, which Borrower, or any of its successors, assigns, or other legal representatives may now or hereafter own, hold, have or claim to have against the Releasees or any of them for, upon, or by reason of any circumstance, action, cause or thing whatsoever which arises at any time on or prior to the day and date of this Amendment, including, without limitation, for or on account of, or in relation to, or in any way in connection with the Loan and Security Agreement, or any of the other Loan Documents or transactions thereunder or related thereto.  Borrower understands, acknowledges and agrees that the release set forth above may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted or attempted in breach of the provisions of such release.  Borrower agrees that no fact, event, circumstance, evidence or transaction which could now be asserted or which may hereafter be discovered shall affect in any manner the final, absolute and unconditional nature of the release set forth above.

NO RELIANCE

.  Borrower hereby acknowledges and confirms to Collateral Agent and the Lenders that Borrower is executing this Amendment on the basis of its own investigation and for its own reasons without reliance upon any agreement, representation, understanding or communication by or on behalf of any other Person.

COSTS AND EXPENSES

.  Borrower agrees to pay to Collateral Agent within ten (10) days of its receipt of an invoice (or on the date hereof to the extent invoiced on or prior to the date hereof), the out-of-pocket costs and expenses of Collateral Agent and the Lenders party hereto, and the fees and disbursements of counsel to Collateral Agent and the Lenders party hereto (including reasonable allocated costs of internal counsel), in connection with the negotiation, preparation, execution and delivery of this Amendment and any other documents to be delivered in connection herewith on the date hereof or after such date.

B

INDING EFFECT.  This Amendment binds and is for the benefit of the successors and permitted assigns of each party.

4

GOVERNING LAW

.  THIS AMENDMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL IN ALL RESPECTS BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (WITHOUT REGARD TO THE CONFLICT OF LAWS PRINCIPLES THAT WOULD RESULT IN THE APPLICATION OF ANY LAW OTHER THAN THE LAW OF SUCH STATE), INCLUDING ALL MATTERS OF CONSTRUCTION, VALIDITY AND PERFORMANCE.

COMPLETE AGREEMENT; AMENDMENTS

.  This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements with respect to such subject matter.  All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Amendment and the Loan Documents merge into this Amendment and the Loan Documents.

SEVERABILITY OF PROVISIONS

.  Each provision of this Amendment is severable from every other provision in determining the enforceability of any provision.

COUNTERPARTS

.  This Amendment may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Consent.  Delivery of an executed counterpart of a signature page of this Amendment by facsimile, portable document format (.pdf) or other electronic transmission will be as effective as delivery of a manually executed counterpart hereof.

LOAN DOCUMENTS

.  This Amendment and the documents related thereto shall constitute Loan Documents.

ELECTRONIC EXECUTION OF CERTAIN OTHER DOCUMENTS

.  The words “execution,” “execute”, “signed,” “signature,” and words of like import in or related to any document to be signed in connection with this Amendment and the transactions contemplated hereby shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by Collateral Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.

[Balance of Page Intentionally Left Blank; Signature Pages Follow]

5

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered as of the day and year specified at the beginning hereof.

BORROWER:

ALIMERA SCIENCES, INC.

By: /s/ J. Philip Jones
Name: J. Philip Jones
Title:   CFO

[Signature Page to Third Amendment to Loan and Security Agreement]

COLLATERAL AGENT AND LENDER:

SLR INVESTMENT CORP.

By: /s/ Anthony Storino
Name:  Anthony Storino
Title:  Authorized Signatory

[Signature Page to Third Amendment to Loan and Security Agreement]

LENDERS:

SUNS SPV LLC

By: /s/ Anthony Storino
Name:  Anthony Storino
Title:  Authorized Signatory

SCP PRIVATE CREDIT INCOME FUND SPV, LLC

By: /s/ Anthony Storino
Name:  Anthony Storino
Title:  Authorized Signatory

SCP PRIVATE CREDIT INCOME BDC SPV LLC

By: /s/ Anthony Storino
Name:  Anthony Storino
Title:  Authorized Signatory

SCP PRIVATE CORPORATE LENDING FUND SPV LLC

By: /s/ Anthony Storino
Name:  Anthony Storino
Title:  Authorized Signatory

SCP SF DEBT FUND L.P.

By: /s/ Anthony Storino
Name:  Anthony Storino
Title:  Authorized Signatory

SCP CAYMAN DEBT MASTER FUND SPV LLC

By: /s/ Anthony Storino
Name:  Anthony Storino
Title:  Authorized Signatory

[Signature Page to Third Amendment to Loan and Security Agreement]

EX-31.1

EXHIBIT 31.1

CERTIFICATION

I, Richard S. Eiswirth, Jr., certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Alimera Sciences, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 12, 2022	/s/ Richard S. Eiswirth, Jr.
	Richard S. Eiswirth, Jr.
	President and Chief Executive Officer
	(Principal Executive Officer)

EX-31.2

EXHIBIT 31.2

CERTIFICATION

I, J. Philip Jones, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Alimera Sciences, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May12, 2022	/s/ J. Philip Jones
	J. Philip Jones
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

EX-32.1

EXHIBIT 32.1

Certification

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Alimera Sciences, Inc.(the Company), does hereby certify, to the best of such officer’s knowledge, that:

The Quarterly Report on Form 10-Q for the quarter ended March  31, 2022 (the Form 10-Q) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May12, 2022	/s/ Richard S. Eiswirth, Jr.
	Richard S. Eiswirth, Jr.
	President and Chief Executive Officer
	(Principal Executive Officer)
Date: May12, 2022	/s/ J. Philip Jones
	J. Philip Jones
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. This certification “accompanies” the Form 10-Q to which it relates, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

XML

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2022	May 10, 2022
Document and Entity Information [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Current Fiscal Year End Date	--12-31
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Document Transition Report	false
Entity File Number	001-34703
Entity Registrant Name	Alimera Sciences, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-0028718
Entity Address, Address Line One	6310 Town Square
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	Alpharetta
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30005
City Area Code	678
Local Phone Number	990-5740
Title of 12(b) Security	Common Stock, $0.01 par value per share
Trading Symbol	ALIM
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Smaller Reporting Company	true
Emerging Growth Company	false
Entity Shell Company	false
Entity common stock, shares outstanding (in shares)		7,002,961
Entity Central Index Key	0001267602
Amendment Flag	false
Document Fiscal Period Focus	Q1

XML

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
CURRENT ASSETS:
Cash and cash equivalents	$ 9,946	$ 16,510
Restricted cash	33	34
Accounts receivable, net	18,776	19,128
Prepaid expenses and other current assets	3,546	3,809
Inventory	2,452	2,679
Total current assets	34,753	42,160
NON-CURRENT ASSETS:
Property and equipment, net	2,719	2,783
Right of use assets, net	1,624	1,710
Intangible asset, net	10,419	10,897
Deferred tax asset	134	137
Warrant asset	282	833
TOTAL ASSETS	49,931	58,520
CURRENT LIABILITIES:
Accounts payable	6,604	8,706
Accrued expenses	3,046	3,617
Notes payable	7,105
Finance lease obligations	251	269
Total current liabilities	17,006	12,592
NON-CURRENT LIABILITIES:
Notes payable, net of discount	36,245	43,080
Other non-current liabilities	5,283	5,453
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ DEFICIT:
Common stock, $.01 par value — 150,000,000 shares authorized, 6,992,654 shares issued and outstanding at March 31, 2022 and 6,935,154 shares issued and outstanding at December 31, 2021	70	69
Additional paid-in capital	377,541	377,229
Accumulated deficit	(403,236)	(397,281)
Accumulated other comprehensive loss	(2,205)	(1,849)
TOTAL STOCKHOLDERS’ DEFICIT	(8,603)	(2,605)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	49,931	58,520
Series A convertible preferred stock [Member]
STOCKHOLDERS’ DEFICIT:
Preferred stock, $.01 par value — 10,000,000 shares authorized at March 31, 2022 and December 31, 2021: Series A Convertible Preferred Stock, 1,300,000 authorized and 600,000 issued and outstanding at March 31, 2022 and December 31, 2021; liquidation preference of $24,000 at March 31, 2022 and December 31, 2021	$ 19,227	$ 19,227

XML

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Preferred stock, par value (usd per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Common stock, par value (usd per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	6,992,654	6,935,154
Common stock, shares outstanding (in shares)	6,992,654	6,935,154
Series A convertible preferred stock [Member]
Preferred stock, shares authorized (in shares)	1,300,000	1,300,000
Preferred stock, shares issued (in shares)	600,000	600,000
Preferred stock, shares outstanding (in shares)	600,000	600,000
Preferred stock, liquidation preference	$ 24,000	$ 24,000

XML

Condensed Consolidated Statements Of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Condensed Consolidated Statements Of Operations [Abstract]
PRODUCT REVENUE, NET	$ 11,898	$ 11,214
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION	(1,680)	(1,562)
GROSS PROFIT	10,218	9,652
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES	3,583	3,213
GENERAL AND ADMINISTRATIVE EXPENSES	3,240	3,413
SALES AND MARKETING EXPENSES	6,853	4,818
DEPRECIATION AND AMORTIZATION	689	638
OPERATING EXPENSES	14,365	12,082
LOSS FROM OPERATIONS	(4,147)	(2,430)
INTEREST EXPENSE AND OTHER	(1,364)	(1,343)
UNREALIZED FOREIGN CURRENCY GAIN, NET	108	125
CHANGE IN FAIR VALUE OF WARRANT ASSET	(552)
NET LOSS	$ (5,955)	$ (3,648)
NET LOSS PER SHARE — Basic and diluted	$ (0.85)	$ (0.63)
WEIGHTED AVERAGE SHARES OUTSTANDING — Basic and Diluted	6,990,737	5,755,424

XML

Condensed Consolidated Statements Of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Condensed Consolidated Statements Of Comprehensive Loss [Abstract]
NET LOSS	$ (5,955)	$ (3,648)
OTHER COMPREHENSIVE LOSS
Foreign currency translation adjustments	(356)	(597)
TOTAL OTHER COMPREHENSIVE LOSS	(356)	(597)
COMPREHENSIVE LOSS	$ (6,311)	$ (4,245)

XML

Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (5,955)	$ (3,648)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	689	638
Unrealized foreign currency transaction gain, net	(108)	(125)
Amortization of debt discount and deferred financing costs	271	240
Stock-based compensation expense	312	262
Change in fair value of warrant asset	552
Changes in assets and liabilities:
Accounts receivable	184	1,335
Prepaid expenses and other current assets	265	(35)
Inventory	203	106
Accounts payable	(1,992)	(1,003)
Accrued expenses and other current liabilities	(541)	(259)
Other long-term liabilities	(93)	(12)
Net cash used in operating activities	(6,213)	(2,501)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(149)	(84)
Net cash used in investing activities	(149)	(84)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments on finance lease obligations	(62)	(57)
Net cash used in financing activities	(62)	(57)
EFFECT OF EXCHANGE RATES ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH	(141)	(299)
NET CHANGE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH	(6,565)	(2,941)
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH — Beginning of period	16,544	11,242
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH — End of period	9,979	8,301
SUPPLEMENTAL DISCLOSURES:
Cash paid for interest	1,061	1,061
Cash paid for income taxes	18	4
Supplemental schedule of non-cash investing and financing activities:
Note payable end of term payment accrued but unpaid	$ 2,250	$ 2,250

XML

Condensed Consolidated Statements Of Changes in Shareholders' Deficit - USD ($) $ in Thousands	Common Stock [Member]	Preferred Stock [Member] Series A convertible preferred stock [Member]	Additional Paid-In Capital [Member]	Common Stock Warrants [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Total
Beginning balance (in shares) at Dec. 31, 2020	5,719,367	600,000
Beginning balance at Dec. 31, 2020	$ 57	$ 19,227	$ 365,830	$ 370	$ (392,909)	$ (553)	$ (7,978)
Issuance of common stock, net of issuance costs (in shares)	45,000
Issuance of common stock, net of issuance costs	$ 1						$ 1
Stock option exercises (in shares)	58						58
Forfeitures of restricted stock (in shares)	(10,933)
Stock-based compensation expense			262				$ 262
Net loss					(3,648)		(3,648)
Foreign currency translation adjustments						(597)	(597)
Ending balance (in shares) at Mar. 31, 2021	5,753,492	600,000
Ending balance at Mar. 31, 2021	$ 58	$ 19,227	366,092	$ 370	(396,557)	(1,150)	(11,960)
Beginning balance (in shares) at Dec. 31, 2021	6,935,154	600,000
Beginning balance at Dec. 31, 2021	$ 69	$ 19,227	377,229		(397,281)	(1,849)	(2,605)
Issuance of common stock, net of issuance costs (in shares)	57,500
Issuance of common stock, net of issuance costs	$ 1						$ 1
Stock option exercises (in shares)
Stock-based compensation expense			312				$ 312
Net loss					(5,955)		(5,955)
Foreign currency translation adjustments						(356)	(356)
Ending balance (in shares) at Mar. 31, 2022	6,992,654	600,000
Ending balance at Mar. 31, 2022	$ 70	$ 19,227	$ 377,541		$ (403,236)	$ (2,205)	$ (8,603)

XML

Nature Of Operations	3 Months Ended
	Mar. 31, 2022
Nature Of Operations [Abstract]
Nature Of Operations	1. NATURE OF OPERATIONS Alimera Sciences, Inc., together with its wholly owned subsidiaries (the Company), is a pharmaceutical company that specializes in the commercialization and development of ophthalmic pharmaceuticals. The Company was formed on June 4, 2003 under the laws of the State of Delaware. The Company presently focuses on diseases affecting the retina, because the Company believes these diseases are not well treated with current therapies and affect millions of people globally. The Company’s only product is ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg, which has received marketing authorization and reimbursement in 24 countries for the treatment of diabetic macular edema (DME). In the U.S. and certain other countries outside Europe, ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. In 17 countries in Europe, ILUVIEN is indicated for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies. In addition, ILUVIEN has received marketing authorization in 17 European countries and reimbursement in five countries for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment (NIU-PS). The Company markets ILUVIEN directly in the U.S., Germany, the U.K., Portugal and Ireland, and has made ILUVIEN available in the Nordic Region (Denmark, Finland, Norway and Sweden) with the support of an exclusive wholesaler. In addition, the Company has entered into various agreements under which distributors are providing or will provide regulatory, reimbursement and sales and marketing support for ILUVIEN in Austria, Belgium, the Czech Republic, France, Italy, Luxembourg, the Netherlands, Spain, Australia, New Zealand and several countries in the Middle East. In addition, the Company has granted an exclusive license to Ocumension Therapeutics for the development and commercialization of the Company’s 0.19mg fluocinolone acetonide intravitreal injection in China, East Asia and the Western Pacific. Effects of the COVID-19 Pandemic The public health crisis caused by the COVID-19 pandemic and the measures being taken by governments, businesses, and the public at large to limit the COVID-19 pandemic’s spread have had, and the Company expects will continue to have to some degree, certain negative effects on, and present certain risks to, the Company’s business. These limitations and other effects of the COVID-19 pandemic have had an adverse impact on the Company’s revenues beginning late in the first quarter of 2020 and continuing through the date of this report. These factors may continue to adversely impact the Company’s revenue, and the extent and duration of that impact is uncertain, particularly in light of the emergence of COVID-19 variants that may increase the transmissibility of the coronavirus or be more deadly, or both. Depending on the duration of these limitations and the severity and duration of other effects of the COVID-19 pandemic, the Company’s liquidity and financial condition may be adversely affected in the future as well. This uncertainty could have an impact in future periods on certain estimates used in the preparation of the Company’s quarterly financial results, including impairment of intangible assets, the income tax provision and realizability of certain receivables and the prospective compliance with the Company’s covenants in its loan agreement. In response to the COVID-19 pandemic, the Company has implemented measures to mitigate the impact of the pandemic on its financial position and operations. These measures include the following: •The Company is continuing to monitor the effects of the SARS-CoV-2 variants and to increase its engagement with its customers to mitigate any anticipated loss of revenue in those markets that may be affected. •The Company is investing in e-marketing and in enhancing its capabilities to conduct meetings virtually as well as in person.

XML

Basis Of Presentation

3 Months Ended

Mar. 31, 2022

Basis Of Presentation [Abstract]

Basis Of Presentation

2. BASIS OF PRESENTATION

The Company has prepared the accompanying unaudited interim condensed consolidated financial statements and notes thereto (Interim Financial Statements) in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, these Interim Financial Statements do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of the Company’s management, the accompanying Interim Financial Statements reflect all adjustments, which include normal recurring adjustments, necessary to present fairly the Company’s interim financial information.

The accompanying Interim Financial Statements and related notes should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2021 and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the SEC on March 23, 2022 (the 2021 Form 10-K). The financial results for any interim period are not necessarily indicative of the expected financial results for the full year.

XML

Summary Of Significant Accounting Policies

3 Months Ended

Mar. 31, 2022

Summary Of Significant Accounting Policies [Abstract]

Summary Of Significant Accounting Policies

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company’s accounting policies followed for quarterly financial reporting are the same as those disclosed in the Notes to Financial Statements included in the 2021 Form 10-K.

Adoption of New Accounting Standard

In August 2020, the FASB issued Accounting Standards Update (ASU) 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This standard simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The standard requires entities to provide expanded disclosures about the terms and features of convertible instruments and amends certain guidance in ASC 260 on the computation of EPS for convertible instruments and contracts on an entity’s own equity. The standard became effective for the Company on January 1, 2022. The adoption of this guidance did not have a material impact on the Company’s financial statements.

Accounting Standards Issued but Not Yet Effective

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (ASC 326): Measurement of Credit Losses on Financial Instruments. This ASU replaces the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. The standard becomes effective for the Company on January 1, 2023. The Company does not anticipate the adoption of this ASU will have a material impact on its financial statements.

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (ASC 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This standard provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The standard is available until December 31, 2022. The Company does not anticipate the adoption of this ASU will have a material impact on the Company’s financial statements.

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The amendments in this ASU require that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers (ASC 606). The amendments in this ASU are effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company does not anticipate the adoption of this ASU will have a material impact on its financial statements.

 

XML

Revenue Recognition

3 Months Ended

Mar. 31, 2022

Revenue Recognition [Abstract]

Revenue Recognition

4. REVENUE RECOGNITION

Overview

The Company recognizes revenue when a customer obtains control of the related good or service. The amount recognized reflects the consideration the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following steps as outlined in the guidance: (1) identify the contract with the customer, (2) identify the performance obligations within the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when the entity satisfies a performance obligation. At the inception of a contract, the contract is evaluated to determine if it falls within the scope of ASC 606, followed by the Company’s assessment of the goods or services promised within each contract, assessment of whether the promised good or service is distinct and determination of the performance obligations. The Company then recognizes revenue based on the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.

If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions related to the performance obligations.

Net Product Sales

The Company sells its products to major pharmaceutical distributors, pharmacies, hospitals and wholesalers (collectively, its Customers). In addition to distribution agreements with Customers, the Company enters into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company’s products. The Company recognizes revenues from product sales at a point in time when the Customer obtains control, typically upon delivery. The Company accrues for fulfillment costs when the related revenue is recognized. Taxes collected from Customers relating to product sales and remitted to governmental authorities are excluded from revenues.

Estimates of Variable Consideration

Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for reserves related to statutory rebates to State Medicaid and other government agencies; commercial rebates and fees to Managed Care Organizations (MCOs), Group Purchasing Organizations (GPOs), distributors, and specialty pharmacies; product returns; sales discounts (including trade discounts); distributor costs; wholesaler chargebacks; and allowances for patient assistance programs relating to the Company’s sales of its products.

These reserves are based on estimates of the amounts earned or to be claimed on the related sales. Management’s estimates take into consideration historical experience, current contractual and statutory requirements, specific known market events and trends, industry data, and Customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the net sales price is limited to the amount that is probable not to result in a significant reversal in the amount of the cumulative revenue recognized in a future period. If actual results vary, the Company may adjust these estimates, which could have an effect on earnings in the period of adjustment.

With respect to the Company’s international contracts with third-party distributors, certain contracts have elements of variable consideration, and management reviews those contracts on a regular basis and makes estimates of revenue based on historical ordering patterns and known market trends and data. The amount of variable consideration included in net sales in each period could vary depending on the terms of these contracts and the probability of reversal in future periods.

Consideration Payable to Customers

Distribution service fees are payments issued to distributors for compliance with various contractually-defined inventory management practices or services provided to support patient access to a product. Distribution service fees reserves are based on the terms of each individual contract and are classified within accrued expenses and are recorded as a reduction of revenue.

Product Returns

The Company’s policies provide for product returns in the following circumstances: (a) expiration of shelf life on certain products; (b) product damaged while in the Customer’s possession; and (c) following product recalls. Generally, returns for expired product are accepted three months before and up to one year after the expiration date of the related product, and the related product is destroyed after it is returned. The Company may either refund the sales price paid by the Customer by issuing a credit or exchange the returned product for replacement inventory. The Company typically does not provide cash refunds. The Company estimates the proportion of recorded revenue that will result in a return by considering relevant factors, including historical returns experience, the estimated level of inventory in the distribution channel, the shelf life of products and product recalls, if any.

The estimation process for product returns involves, in each case, several interrelating assumptions, which vary for each Customer. The Company estimates the amount of its product sales that may be returned by its Customers and records this estimate as a reduction of revenue from product sales in the period the related revenue is recognized, and because this returned product cannot be resold, there is no corresponding asset for product returns. To date, product returns have been minimal.

License Revenue

The Company enters into agreements in which it licenses certain rights to its products to partner companies that act as distributors. The terms of the license agreement may include payment to the Company of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. The Company recognizes revenue from upfront payments at a point in time, typically upon fulfilling the delivery of the associated intellectual property to the customer.

The Company will recognize sales-based milestone payments as revenue upon the achievement of the cumulative sales amount specified in the contract in accordance with ASC 606. For those milestone payments which are contingent on the occurrence of particular future events, the Company determines that these need to be considered for inclusion in the calculation of total consideration from the contract as a component of variable consideration using the expected value method. As such, the Company assesses each milestone to determine the probability of and substance behind achieving each milestone. Given the inherent uncertainty associated with these future events, the Company will not recognize revenue from such milestones until there is a high probability of occurrence, which typically occurs near or upon achievement of the event.

Customer Payment Obligations

The Company receives payments from its Customers based on billing schedules established in each contract, which vary across the Company’s markets, but generally range between 30 to 120 days. Occasionally, the Company extends the timing of its receipt of payment from the Company’s international Customers. Amounts are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation is that the Customer will pay for the product or services in one year or less of receiving those products or services.

 

XML

Leases

3 Months Ended

Mar. 31, 2022

Leases [Abstract]

Leases

5. LEASES

The Company evaluates all of its contracts to determine whether it is or contains a lease at inception. The Company reviews its contracts for options to extend, terminate or purchase any right of use assets and accounts for these, as applicable, at inception of the contract. Upon adoption of ASC 842, the Company elected the transition package of three practical expedients permitted within the standard. In accordance with the package of practical expedients, the Company did not reassess initial direct costs, lease classification or whether its contracts contain or are leases. The Company made an accounting policy election not to recognize right of use assets and liabilities for leases with a term of 12 months or less, or those that do not meet the Company’s capitalization threshold, unless the leases include options to renew or purchase the underlying asset that are reasonably certain to be exercised. Lease costs associated with those leases are recognized as incurred. The Company has also chosen the practical expedient that allows it to combine lease and non-lease components as a single lease component.

Lease renewal options are not recognized as part of the lease liability until the Company determines it is reasonably certain it will exercise any applicable renewal options. The Company has determined it is not reasonably certain it will exercise any applicable renewal options. The Company has not recorded any liability for renewal options in these consolidated financial statements. The useful lives of leased assets as well as leasehold improvements, if any, are limited by the expected lease term.

Operating Leases

The Company’s operating lease activities primarily consist of leases for office space in the U.S., the U.K., Ireland and Germany. Most of these leases include options to renew, with renewal terms generally ranging from one to eight years. The exercise of lease renewal options is at the Company’s sole discretion. Certain of the Company’s operating lease agreements include variable lease costs that are based on common area maintenance and property taxes. The Company expenses these payments as incurred. The Company’s operating lease agreements do not contain any material residual value guarantees or material restrictive covenants.

Supplemental balance sheet information as of March 31, 2022 and December 31, 2021 for the Company’s operating leases is as follows:

	March 31,		December 31,
	2022		2021
	(In thousands)
NON-CURRENT ASSETS:
Right of use assets, net	$	1,624	$	1,710
Total lease assets	$	1,624	$	1,710
CURRENT LIABILITIES:
Accrued expenses	$	323	$	220
NON-CURRENT LIABILITIES:
Other non-current liabilities		2,618		2,735
Total lease liabilities	$	2,941	$	2,955

The Company’s operating lease cost for the three months ended March 31, 2022 was $138,000 and is included in general and administrative expenses in its condensed consolidated statement of operations. The Company’s operating lease cost for the three months ended March 31, 2021 was $118,000 and is included in general and administrative expenses in its condensed consolidated statement of operations.

As of March 31, 2022, a schedule of maturity of lease liabilities under all of the Company’s operating leases is as follows:

Years Ending December 31	(In thousands)
2022 (remaining)	$	201
2023		716
2024		687
2025		474
2026		488
Thereafter		1,555
Total		4,121
Less amount representing interest		(1,180)
Present value of minimum lease payments		2,941
Less current portion (as a portion of accrued expenses)		(323)
Non-current portion (as a portion of other non-current liabilities)	$	2,618

Cash paid for operating leases was $68,000 during the three months ended March 31, 2022. No right-of-use assets were obtained in connection with operating leases for the three months ended March 31, 2022. Cash paid for operating leases was $149,000 during the three months ended March 31, 2021. No right-of-use assets were obtained in connection with operating leases for the three months ended March 31, 2021.

As of March 31, 2022, the weighted average remaining lease terms of the Company’s operating leases was 6.9 years. The weighted average discount rate used to determine the lease liabilities was 9.5%.

Finance Leases

The Company’s finance lease activities primarily consist of leases for office equipment and automobiles. Property and equipment leases are capitalized at the lesser of fair market value or the present value of the minimum lease payments at the inception of the leases using the Company’s incremental borrowing rate. The Company’s finance lease agreements do not contain any material residual value guarantees or material restrictive covenants.

Supplemental balance sheet information as of March 31, 2022 and December 31, 2021 for the Company’s finance leases is as follows:

	March 31,		December 31,
	2022		2021
	(In thousands)
NON-CURRENT ASSETS:
Property and equipment, net	$	302	$	392
Total lease assets	$	302	$	392
CURRENT LIABILITIES:
Finance lease obligations	$	251	$	269
NON-CURRENT LIABILITIES:
Finance lease obligations — less current portion		181		225
Total lease liabilities	$	432	$	494

Depreciation expense associated with property and equipment under finance leases was approximately $94,000 and $101,000 for the three months ended March 31, 2022 and 2021, respectively. Interest expense associated with finance leases was $14,000 for the three months ended March 31, 2022 and 2021.

As of March 31, 2022, a schedule of maturity of lease liabilities under finance leases, together with the present value of minimum lease payments, is as follows:

Years Ending December 31	(In thousands)
2022 (remaining)	$	279
2023		236
Total		515
Less amount representing interest		(83)
Present value of minimum lease payments		432
Less current portion		(251)
Non-current portion	$	181

Cash paid for finance leases was $98,000 during the three months ended March 31, 2022. No property or equipment was obtained in exchange for finance leases during the three months ended March 31, 2022.

As of March 31, 2022, the weighted average remaining lease terms of the Company’s finance leases was 0.9 years. The weighted average discount rate used to determine the finance lease liabilities was 9.4%.

 

XML

Going Concern

3 Months Ended

Mar. 31, 2022

Going Concern [Abstract]

Going Concern

6. GOING CONCERN

The accompanying Interim Financial Statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Interim Financial Statements do not include any adjustments that might result from the outcome of this uncertainty.

To date, the Company has incurred recurring losses and has accumulated a deficit of $403,236,000 from inception through March 31, 2022. As of March 31, 2022, the Company had approximately $9,946,000 in cash and cash equivalents.

Further, the Company must maintain compliance with the debt covenants of its $45,000,000 Loan and Security Agreement dated December 31, 2019 with SLR Investment Corp., as amended (the 2019 Loan Agreement; see Note 10). In management’s opinion, the uncertainty regarding future revenues raises substantial doubt about the Company’s ability to continue as a going concern without access to additional debt and/or equity financing over the course of the next twelve months.

The Company’s operations and thus its net product revenues have continued to be adversely affected by the COVID-19 pandemic. During the six months ended December 31, 2021 and September 30, 2021, the Company did not generate sufficient revenue to meet the trailing six-month revenue covenant included in the 2019 Loan Agreement. The lenders provided a consent that permitted the Company not

to maintain the revenue covenant as of December 31, 2021 and September 30, 2021 and waived any event of default that has occurred or may be deemed to have occurred.

The Company met the trailing six-month revenue covenant included in the 2019 Loan Agreement for the six-month period ended March 31, 2022 and expects to comply with the revenue covenant at the next reportable date, which is June 30, 2022, and through one year after the filing date of this Quarterly Report on Form 10-Q, although the Company can give no assurances in that regard. Due to the remaining uncertainty surrounding the COVID-19 pandemic, it is possible that the Company will fail to comply with the revenue covenant. If the Company fails to comply with the revenue covenant and the lenders do not provide a consent and waiver, acceleration of the maturity of the loan is one of the remedies available to the lenders. If the lenders accelerate the maturity of the loan, the Company would be forced to find alternative financing or enter into an alternative agreement with the lenders. The Company cannot be sure that alternative financing will be available when needed or that, if available, the alternative financing could be obtained on terms that are not significantly detrimental to the Company or its stockholders.

To meet the Company’s future working capital needs, the Company may need to raise additional debt or equity financing. While the Company from time to time has been able to raise additional capital through issuance of equity and/or debt financing, the Company cannot guarantee that it will be able to maintain debt compliance, raise additional equity, contain or reduce expenses, or increase revenue. Accordingly, there is substantial doubt about the Company’s ability to continue as a going concern within one year after these Interim Financial Statements are issued.

 

XML

Inventory

3 Months Ended

Mar. 31, 2022

Inventory [Abstract]

Inventory

7. INVENTORY

Inventory consisted of the following:

	March 31,		December 31,
	2022		2021
	(In thousands)
Component parts (1)	$	157	$	200
Work-in-process (2)		684		1,416
Finished goods		1,611		1,063
Total Inventory	$	2,452	$	2,679

(1)    Component parts inventory consists of manufactured components of the ILUVIEN applicator.

(2)    Work-in-process consists of completed units of ILUVIEN that are undergoing, but have not completed, quality assurance testing or stability testing as required by U.S. or EEA regulatory authorities.

 

XML

Intangible Asset

3 Months Ended

Mar. 31, 2022

Intangible Asset [Abstract]

Intangible Asset

8. INTANGIBLE ASSET

As a result of the approval of ILUVIEN by the U.S. Food and Drug Administration (FDA) in 2014, the Company was required to pay EyePoint Pharmaceuticals, Inc. (EyePoint) a milestone payment of $25,000,000 (see Note 9).

The gross carrying amount of the intangible asset is $25,000,000, which is being amortized over approximately 13 years from the payment date. The amortization expense related to the intangible asset was approximately $489,000 for both the three months ended March 31, 2022 and 2021, respectively. The net book value of the intangible asset was $10,419,000 and $10,897,000 as of March 31, 2022 and December 31, 2021, respectively.

The estimated future amortization expense as of March 31, 2022 for the remaining periods in the next five years and thereafter is as follows:

Years Ending December 31	(In thousands)
2022 (remaining)	$	1,462
2023		1,940
2024		1,946
2025		1,940
2026		1,940
Thereafter		1,191
Total	$	10,419

 

XML

License Agreements

3 Months Ended

Mar. 31, 2022

License Agreements [Abstract]

License Agreements

9. LICENSE AGREEMENTS

EyePoint Agreement

In February 2005, the Company entered into an agreement with EyePoint (formerly known as pSivida US, Inc.) for the use of fluocinolone acetonide (FAc) in EyePoint’s proprietary insert technology. This agreement was subsequently amended a number of times (as amended, the EyePoint Agreement). The EyePoint Agreement provides the Company with a worldwide exclusive license to utilize certain underlying technology used in the development and commercialization of ILUVIEN.

In July 2017, the Company amended and restated its EyePoint license agreement, which was made effective July 1, 2017 (the New Collaboration Agreement). Under the New Collaboration Agreement, the Company has the right to the technology underlying ILUVIEN for the treatment of (a) human eye diseases, including uveitis, in Europe, the Middle East, and Africa, and (b) human eye diseases other than uveitis worldwide. The New Collaboration Agreement converted the Company’s previous profit share obligation to a royalty payable on global net revenues of ILUVIEN.

Following the signing of the New Collaboration Agreement, the Company retained a right to recover up to $15,000,000 of commercialization costs that were incurred prior to profitability of ILUVIEN and to offset a portion of future payments owed to EyePoint with these accumulated commercialization costs, referred to as the Future Offset. Due to the uncertainty of future net profits, the Company has fully reserved the Future Offset in the accompanying Interim Financial Statements. In March 2019, pursuant to the New Collaboration Agreement, the Company forgave $5,000,000 of the Future Offset in connection with the approval of ILUVIEN for NIU-PS in the U.K. As of March 31, 2022, the balance of the Future Offset was approximately $7,324,000.

During each of the three months ended March 31, 2022 and 2021, the Company’s net royalty expense payable to EyePoint was 5.2%, which was reduced from 6% due to the recoverable balance of the Future Offset. The Company is required to pay an additional 2% royalty on future global net revenues and other related consideration in excess of $75,000,000 in any year. During the three months ended March 31, 2022, the Company recognized approximately $617,000 of royalty expense, which is included in cost of goods sold, excluding depreciation and amortization. As of March 31, 2022, approximately $617,000 of this royalty expense was included in the Company’s accounts payable. During the three months ended March 31, 2021, the Company recognized approximately $584,000 of royalty expense, which is included in cost of goods sold, excluding depreciation and amortization.

Ocumension License Agreement

On April 14, 2021, the Company entered into an exclusive license agreement (the License Agreement) with Ocumension (Hong Kong) Limited (“Ocumension HK”), a wholly owned subsidiary of Ocumension Therapeutics, for the development and commercialization under Ocumension HK’s own brand name(s), either directly or through its affiliates or approved third-party sublicensees, of the Company’s 190 microgram fluocinolone acetonide intravitreal implant in applicator (the “Product”; currently marketed in the United States, Europe, and the Middle East as “ILUVIEN®”) for the treatment and prevention of eye diseases in humans, other than uveitis, in a specified territory. The “Territory” is defined as the People’s Republic of China, including Hong Kong SAR and Macau SAR, region of Taiwan, South Korea, Brunei, Cambodia, East Timor, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, and Vietnam.

The Company received a nonrefundable upfront payment of $10,000,000 from Ocumension HK and may in the future receive additional sales-based milestone payments totaling up to $89,000,000 upon the achievement by Ocumension HK of certain specified sales milestones during the term of the License Agreement. The Company’s receipt of future milestone payments depends upon whether Ocumension HK is able to successfully complete product development and commercialization in the Territory, which requires, among other things, obtaining necessary regulatory approvals and appropriate reimbursement pricing in the various countries and jurisdictions in the Territory, a process that may take several years. During the year ended December 31, 2021, the Company recognized $11,048,000 in license revenue from the Ocumension transaction (including the value of a warrant subscription agreement, which Alimera received as consideration, for Alimera to purchase 1,000,000 shares of Ocumension Therapeutics during a period of four years), in accordance with ASC 606, Revenue from Contracts with Customers, with the remaining approximate $300,000 in consideration classified as deferred revenue that will be recognized over the remaining term of the license agreement once Ocumension begins to sell products.

The term of the License will continue (a) until the 10th anniversary of the latest first commercial sale of the Product in any country or jurisdiction in the Territory or (b) for as long as Ocumension HK is commercializing the Product in any part of the Territory, whichever is later. The term is subject to the Company’s right to partially terminate the Agreement beginning on the 10th anniversary of the effective date with respect to any country or jurisdiction in the Territory in which Ocumension has not achieved at the time of termination first commercial sale and is not continuing to commercialize the Product. Ocumension will purchase Product from the Company at a fixed transfer price without royalty obligation on future sale (other than milestone payments as described above). Ocumension HK is responsible for all costs of development and commercialization in the Territory.

When the Company entered into the license agreement, it also entered into a share purchase agreement and a warrant subscription agreement (warrant agreement), which are discussed in Note 16.

 

XML

Loan Agreements

3 Months Ended

Mar. 31, 2022

Loan Agreements [Abstract]

Loan Agreements

10. LOAN AGREEMENTS

Loan Agreements with SLR Investment Corp. (formerly named Solar Capital Ltd.)

As of January 5, 2018, the Company entered into a $40,000,000 loan and security agreement with Solar Capital Ltd., as Collateral Agent, and the parties signatory thereto from time to time as Lenders, including Solar Capital Ltd. in its capacity as a Lender (the 2018 Loan Agreement). On December 31, 2019, the Company refinanced the 2018 Loan Agreement by entering into a $45,000,000 loan and security agreement (as amended, the 2019 Loan Agreement) with Solar Capital Ltd., as Collateral Agent, and the parties signing the Loan Agreement from time to time as Lenders, including Solar Capital Ltd. in its capacity as a Lender (collectively, the Lenders). Under the 2019 Loan Agreement, the Company borrowed $42,500,000 on December 31, 2019 and borrowed the remaining $2,500,000 on February 21, 2020. The two borrowings under the 2019 Loan Agreement totaled $45,000,000 and are referred to as the SLR Loan, given that Solar Capital Ltd. changed its name to SLR Investment Corp. (SLR) in February 2021. The SLR Loan matures on July 1, 2024. The Company used the initial proceeds of the SLR Loan to pay off the outstanding loan under the 2018 Loan Agreement, along with related prepayment, legal and other fees and expenses of approximately $2,300,000, which included $2,200,000 in fees to SLR.

2018 Exit Fee Agreement

Notwithstanding the repayment of the outstanding loan under the 2018 Loan Agreement with part of the SLR Loan, the Company remains obligated to pay additional fees under the Exit Fee Agreement (2018 Exit Fee Agreement) dated as of January 5, 2018 by and among the Company, SLR, as Agent, and the Lenders. The 2018 Exit Fee Agreement survived the termination of the 2018 Loan Agreement upon the repayment of the outstanding loan under the 2018 Loan Agreement and has a term of 10 years. The Company is obligated to pay up to, but no more than, $2,000,000 in fees under the 2018 Exit Fee Agreement.

Specifically, the Company is obligated to pay an exit fee of $2,000,000 on a “change in control” (as defined in the 2018 Exit Fee Agreement). To the extent that the Company has not already paid the $2,000,000 fee, the Company is also obligated to pay a fee of $1,000,000 on achieving each of the following milestones:

• first, if the Company achieves revenues of $80,000,000 or more from the sale of its ILUVIEN product in the ordinary course of business to third party customers, measured on a trailing 12-month basis during the term of the agreement, tested at the end of each month; and

• second, if the Company achieves revenues of $100,000,000 or more from the sale of its ILUVIEN product in the ordinary course of business to third party customers, measured in the same manner.

2019 Exit Fee Agreement

The Company is also obligated to pay additional fees under the Exit Fee Agreement dated as of December 31, 2019 by and among the Company, SLR as Agent, and the Lenders (2019 Exit Fee Agreement). The 2019 Exit Fee Agreement will survive the termination of the 2019 Loan Agreement and has a term of 10 years. The Company will be obligated to pay a $675,000 exit fee upon the occurrence of an exit event, which generally means a change in control, as defined in the 2019 Exit Fee Agreement.

First Amendment to 2019 Loan Agreement

On May 1, 2020, the Company entered into a First Amendment (the First Amendment) to the 2019 Loan Agreement. The First Amendment also included revised covenants that applied to the Company’s financial performance during 2020, all of which were met. The First Amendment, among other things, required that a revenue covenant be measured at March 31, 2021 and at the last day of each quarter thereafter, with the minimum revenue amount equal to a percentage of the Company’s projected revenues in accordance with a plan the Company submitted to the Collateral Agent in February 2021, and with such plan to be approved by the Company’s board of directors (the Board) and SLR in its sole discretion.

Second Amendment to 2019 Loan Agreement

On March 30, 2021, the Company entered into a Second Amendment (the Second Amendment) to the 2019 Loan Agreement. The Second Amendment, among other things:

(a)reflected the Collateral Agent’s consent to the Company’s delivery of Board-approved annual financial projections for 2021 by April 1, 2021 (which the Company delivered in a timely manner);

(b)specified the minimum revenue amount, calculated on a trailing six-month basis and tested at the end of each calendar quarter in 2021, that the Company must achieve for each such period (the Revenue Covenant);

(c)required that the Revenue Covenant be tested at March 31, 2022 and at the last day of each quarter thereafter, with the minimum revenue amount equal to a percentage of the Company’s projected revenues in accordance with an annual plan that the Company must submit to the Collateral Agent by January 15th of such year, such plan to be approved by the Board and the Collateral Agent in its sole discretion; and

(d)provided that in future years the Company must deliver to the Collateral Agent and the Lenders as soon as available after approval thereof by the Board, but no later than the earlier of (x) 15 days after such approval and (y) February 28 of such year, the Company’s annual financial projections for the entire current fiscal year as approved by the Board; provided that any revisions to such projections approved by the Board shall be delivered to the Collateral Agent and the Lenders no later than seven days after such approval.

Third Amendment to 2019 Loan Agreement

On February 22, 2022, the Company entered into a Third Amendment to the 2019 Loan Agreement (the Third Amendment), which, among other things:

(a)specified the minimum revenue amount, calculated on a trailing six-month basis and tested at the end of each calendar quarter in 2022, that the Company must achieve for each such period (the Revenue Covenant);

(b)consented to maintaining a lower minimum revenue amount under the Revenue Covenant for the trailing six-month period ended December 31, 2021 than previously required under the 2019 Loan Agreement (and waived any event of default that may have occurred or may be deemed to have occurred as a result of the Company’s lower revenue amount for that period); and

(c)required that the Revenue Covenant be tested at March 31, 2023 and at the last day of each quarter thereafter, with the minimum revenue amount equal to a percentage of the Company’s projected revenues in accordance with an annual plan that the Company must submit to the Collateral Agent by January 15 of such year, such plan to be thereafter approved by the Board and the Collateral Agent in its sole discretion no later than February 28 of such year.

Interest on the 2019 Loan Agreement is payable at the greater of (i) one-month LIBOR or (ii) 1.78%, in either case plus 7.65% per annum. As of March 31, 2022, the interest rate under the 2019 Loan Agreement was 9.43%. The 2019 Loan Agreement provides for interest only payments until January 1, 2023. If the Company meets certain revenue thresholds and no event of default shall have occurred and is continuing, the Company can extend the interest only period an additional six months, ending on June 30, 2023, followed by one year of monthly payments of principal and interest

The Company’s operations and thus its net product revenues have continued to be adversely affected by the COVID-19 pandemic. During each of the six months ended September 30, 2021 and December 31, 2021, the Company did not generate sufficient revenue to meet the trailing six-month Revenue Covenant included in the 2019 Loan Agreement. For each such six-month period, the Lenders provided a consent that permitted the Company not to maintain the Revenue Covenant as of September 30, 2021 and December 31, 2021, respectively, and waived any event of default that may have occurred or may have been deemed to have occurred. The Company was in compliance with the Revenue Covenant as of March 31, 2022 and expects to comply with the Revenue Covenant at the next reportable date, which is June 30, 2022, and throughout 2022, although the Company can give no assurances in that regard. See Note 6.

Modification of Debt

In accordance with the guidance in ASC 470-50, Debt, the Company entered into and accounted for the First Amendment, the Second Amendment and the Third Amendment as modifications and expensed, as they were incurred, legal costs associated with third parties as costs of the modifications. The Company did not capitalize any additional costs associated with the Amendments.

Paycheck Protection Program Loan

On April 22, 2020, the Company received a $1,778,000 loan (the PPP Loan) under the Paycheck Protection Program established by the U.S. Small Business Administration as part of the Coronavirus Aid, Relief and Economic Security Act, or the CARES Act. The PPP Loan was unsecured and was evidenced by a note in favor of HSBC Bank USA, National Association (HSBC) as the lender. On July 21, 2020, the Company submitted an application to HSBC for forgiveness of the PPP Loan. The PPP Loan was forgiven in its entirety, including interest, on April 16, 2021. As a result of forgiveness, the Company recognized a gain on extinguishment of debt of $1,792,000 during the year ended December 31, 2021.

Fair Value of Debt

The weighted average interest rates of the Company’s notes payable approximate the rate at which the Company could obtain alternative financing. Therefore, the carrying amount of the notes approximated their fair value at March 31, 2022 and December 31, 2021.

Hercules Loan Agreement and Related Warrant

In connection with the previous loan with Hercules Capital, Inc. (Hercules), on October 20, 2016, the Company issued a warrant to Hercules Capital, Inc. that granted Hercules the right to purchase up to 30,582 shares of the Company’s common stock at an exercise price of $16.35 per share. The right to exercise this warrant expired on October 20, 2021.

 

XML

Earnings (Loss) Per Share (EPS)

3 Months Ended

Mar. 31, 2022

Earnings (Loss) Per Share (EPS) [Abstract]

Earnings (Loss) Per Share (EPS)

11. EARNINGS (LOSS) PER SHARE (EPS)

The Company follows ASC 260, Earnings Per Share (ASC 260), which requires the reporting of both basic and diluted earnings per share. Because the Company’s preferred stockholders participate in dividends equally with common stockholders (if the Company were to declare and pay dividends), the Company uses the two-class method to calculate EPS. However, the Company’s preferred stockholders are not contractually obligated to share in losses.

Basic EPS is computed by dividing net income or loss available to stockholders by the weighted average number of shares outstanding for the period. Diluted EPS is calculated in accordance with ASC 260 by adjusting weighted average shares outstanding for the dilutive effect of common stock options, restricted stock units and warrants. In periods where a net loss is recorded, no effect is given to potentially dilutive securities, since the effect would be anti-dilutive.

Common stock equivalent securities that would potentially dilute basic EPS in the future, but were not included in the computation of diluted EPS because they were either not classified as participating or would have been anti-dilutive, were as follows:

	March 31,
	2022		2021
Series A convertible preferred stock		601,504		601,504
Common stock warrants		—		30,582
Stock options		1,315,161		1,083,124
Total		1,916,665		1,715,210

XML

Preferred Stock

3 Months Ended

Mar. 31, 2022

Preferred Stock [Abstract]

Preferred Stock

12. PREFERRED STOCK

Series A Convertible Preferred Stock

As of March 31, 2022, there were 600,000 shares of Series A Convertible Preferred Stock issued and outstanding.

XML

Equity Incentive Plans

3 Months Ended

Mar. 31, 2022

Equity Incentive Plans [Abstract]

Equity Incentive Plans

13. EQUITY INCENTIVE PLANS

Under the Company’s 2019 Omnibus Incentive Plan (the 2019 Plan), the Compensation Committee of the Board is authorized to grant equity-based incentive awards that include stock options, restricted stock units (RSUs) and shares of restricted stock to officers, directors, employees and contractors. Equity-based awards are also outstanding under the Company’s 2010 Equity Incentive Plan, although no new awards can be granted under that plan. The Company also has an employee stock purchase plan.

Stock Options

During the three months ended March 31, 2022 and 2021, the Company recorded compensation expense related to stock options of approximately $258,000 and $235,000, respectively. As of March 31, 2022, the total unrecognized compensation cost related to non-vested stock options granted was $1,723,000 and is expected to be recognized over a weighted average period of 2.88 years. The following table presents a summary of stock option activity for the three months ended March 31, 2022 and 2021:

	Three Months Ended
	March 31,
	2022			2021
			Weighted			Weighted
			Average			Average
			Exercise			Exercise
	Options		Price ($)	Options		Price ($)
Options outstanding at beginning of period		1,075,795	23.35		939,379	26.72
Grants		283,550	4.84		187,150	5.02
Forfeitures and expirations		(44,184)	22.36		(43,347)	7.80
Exercises		—	—		(58)	6.75
Options outstanding at period end		1,315,161	19.39		1,083,124	23.73
Options exercisable at period end		810,201	27.92		739,466	31.30
Weighted average per share fair value of options granted during the period	$	3.32		$	3.22

The following table provides additional information related to outstanding stock options as of March 31, 2022:

					Weighted
			Weighted		Average
			Average		Remaining		Aggregate
			Exercise		Contractual		Intrinsic
	Shares		Price ($)		Term		Value ($)
							(In thousands)
Outstanding		1,315,161		19.39		6.42 years		312
Exercisable		810,201		27.92		4.74 years		36
Outstanding, vested and expected to vest		1,247,294		20.15		6.26 years		277

The following table provides additional information related to outstanding stock options as of December 31, 2021:

					Weighted
			Weighted		Average
			Average		Remaining		Aggregate
			Exercise		Contractual		Intrinsic
	Shares		Price ($)		Term		Value ($)
							(In thousands)
Outstanding		1,075,795		23.35		5.56 years		21
Exercisable		809,837		28.76		4.57 years		5
Outstanding, vested and expected to vest		1,043,347		23.88		5.46 years		19

As of March 31, 2022, 686,603 shares remain available for grant under the 2019 Plan.

Restricted Stock and Restricted Stock Units

A summary of restricted stock and restricted stock units (RSU) transactions under the plans are as follows:

	Three Months Ended
	March 31,
	2022				2021
			Weighted				Weighted
			Average				Average
	Restricted		Grant Date		Restricted		Grant Date
	Stock & RSUs		Fair Value ($)		Stock & RSUs		Fair Value ($)
Restricted stock & RSUs outstanding at beginning of period		46,250		5.65		30,086		3.12
Grants		57,500		4.96		45,000		5.01
Vested units		(9,687)		5.01		(25,403)		3.12
Forfeitures		—		—		(10,933)		4.20
Restricted stock & RSUs outstanding at period end		94,063		5.29		38,750		5.01

Employee stock-based compensation expense related to restricted stock and RSUs recognized in accordance with ASC 718, Compensation - Stock Compensation (ASC 718) was $46,000 and $19,000 for the three months ended March 31, 2022 and 2021, respectively.

As of March 31, 2022, the total unrecognized compensation cost related to restricted stock was $429,000 and is expected to be recognized over a weighted average period of 3.29 years.

Employee Stock Purchase Plan

During the three months ended March 31, 2022 and 2021, the Company recorded compensation expense related to its employee stock purchase plan of approximately $8,000 and $8,000, respectively.

 

XML

Income Taxes	3 Months Ended
	Mar. 31, 2022
Income Taxes [Abstract]
Income Taxes	14. INCOME TAXES In accordance with ASC 740, Income Taxes, the Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities at the enacted tax rates in effect for the year in which the differences are expected to reverse. The Company records a valuation allowance against its net deferred tax asset to reduce the net carrying value to an amount that is more likely than not to be realized. At the end of each interim period, the Company makes its best estimate of the effective tax rate expected to be applicable for the full fiscal year. This estimate reflects, among other items, the Company’s best estimate of operating results and foreign currency exchange rates. The Company also applies the provisions for income taxes related to, among other things, accounting for uncertain tax positions and disclosure requirements. There has been no change to the Company’s policy that recognizes potential interest and penalties related to uncertain tax positions. The Company conducts business globally and, as a result, files income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. In the normal course of business, the Company is subject to examination by taxing authorities throughout the world. For the three months ended March 31, 2022, the Company has not recorded income tax expense or benefit. The Company has incurred losses in all material jurisdictions for the current quarter. No tax benefit is expected to be realized for the losses in the United States and the United Kingdom due to the ongoing losses and valuation allowances in these jurisdictions. Tax expense or benefit for income and losses in other jurisdictions (Ireland, Germany, and Portugal) are immaterial for the quarter. At December 31, 2021, the Company had U.S. federal NOL carry-forwards of approximately $143,200,000 and state NOL carry-forwards of approximately $106,700,000 available to reduce future taxable income. The Company’s U.S. federal NOL carry-forwards remain fully reserved as of March 31, 2022. Except for the NOLs generated after 2017, the U.S. federal NOLs not fully utilized will expire at various dates between 2029 and 2038; most state NOL carry-forwards will expire at various dates between 2021 and 2041. Under the Tax Cuts and Jobs Act of 2017, U.S. federal NOLs and some state NOLs generated after 2017 will carryforward indefinitely. As of December 31, 2021, the Company’s U.K. subsidiary is in a net deferred tax asset position primarily due to the step up in tax basis for intangible assets created by the transfer of intellectual property from the Netherlands to the U.K. Based upon the expected pattern of reversal of deferred taxes, it is not more likely than not that these deferred tax assets will be realized. As such, a full valuation allowance is placed against the net deferred tax assets of the U.K. subsidiary. The Company’s Irish subsidiary has a deferred tax asset for net operating loss carryforwards. The Company expects this net operating loss carryforward to be fully realizable in the future based upon the Company’s control of the transfer pricing arrangements. A valuation allowance is not recorded on the deferred tax assets of the Ireland subsidiary. Deferred tax considerations for all other foreign entities are immaterial to the financial statements. The Company anticipates that its foreign subsidiaries will be profitable and have earnings in the future. Once the foreign subsidiaries have earnings, the Company intends to indefinitely reinvest in its foreign subsidiaries all undistributed earnings and original investments in such subsidiaries. As a result, the Company does not expect to record deferred tax liabilities in the future related to excesses of book over tax basis in the stock of its foreign subsidiaries in accordance with ASC 740-30-25. Tax years from 2018 to 2020 remain subject to examination in California, Georgia, Kentucky, Tennessee, Texas and on the federal level, with the exception of the assessment of NOL carry-forwards available for utilization, which can be examined for all years since 2009. The statute of limitations on these years will close when the NOLs expire or when the statute closes on the years in which the NOLs are utilized.

XML

Segment Information

3 Months Ended

Mar. 31, 2022

Segment Information [Abstract]

Segment Information

15. SEGMENT INFORMATION

During the three months ended March 31, 2022 and 2021, two customers within the U.S. segment that are large pharmaceutical distributors accounted for 58% and 50%, respectively, of the Company’s consolidated product revenues. These same two customers within the U.S. segment accounted for approximately 58% and 68% of the Company’s consolidated accounts receivable at March 31, 2022 and at December 31, 2021, respectively.

During the first quarter of 2021, the Chief Executive Officer (CEO), who is the chief operating decision maker (CODM), changed the manner in which the CODM monitors performance, aligns strategies and allocates resources, which resulted in a change in the operating segments. The Company’s operations are now managed as three operating segments: U.S., International and Operating Cost. The Company determined that each of these operating segments represented a reportable segment. Previously, the Company was managed as two operating segments: U.S. and International. In monitoring performance, aligning strategies and allocating resources, the CODM manages and evaluates the Company’s U.S., International and Operating Cost segments based on segment income or loss from operations adjusted for certain non-cash items, such as stock-based compensation expense and depreciation and amortization. Therefore, the Company classifies within Other (a) the non-cash expenses included in research, development and medical affairs expenses; general and administrative expenses; and sales and marketing expenses; and (b) depreciation and amortization.

The Company’s U.S. and International segments represent the sales and marketing, general and administrative and research and development activities dedicated to the respective geographies. The Operating Cost segment primarily represents the general and administrative and research and development activities not specifically associated with the U.S. or International segments and includes expenses such as executive management; information technology administration and support; legal; compliance; clinical studies; and business development.

Each of the Company’s U.S., International and Operating Cost segments is separately managed and is evaluated primarily upon segment income or loss from operations. Other is presented to reconcile to the Company’s consolidated totals. The Company does not report balance sheet information by segment because the CODM does not review that information. The Company allocates certain operating expenses among its reporting segments based on activity-based costing methods. These activity-based costing methods require the Company to make estimates that affect the amount of each expense category that is attributed to each segment. Changes in these estimates will directly affect the amount of expense allocated to each segment and therefore the operating profit of each reporting segment.

The following tables present a summary of the Company’s reporting segments for the three months ended March 31, 2022 and 2021:

	Three Months Ended
	March 31, 2022
	U.S.		International		Operating Cost		Other		Consolidated
	(In thousands)
REVENUE:
PRODUCT REVENUE, NET	$	6,919	$	4,979	$	—	$	—	$	11,898
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION		(815)		(865)		—		—		(1,680)
GROSS PROFIT		6,104		4,114		—		—		10,218
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES		1,170		916		1,461		36		3,583
GENERAL AND ADMINISTRATIVE EXPENSES		317		422		2,283		218		3,240
SALES AND MARKETING EXPENSES		4,674		2,004		117		58		6,853
DEPRECIATION AND AMORTIZATION		—		—		—		689		689
OPERATING EXPENSES		6,161		3,342		3,861		1,001		14,365
SEGMENT INCOME (LOSS) FROM OPERATIONS		(57)		772		(3,861)		(1,001)		(4,147)
OTHER INCOME AND EXPENSES, NET		—		—		—		(1,808)		(1,808)
NET LOSS									$	(5,955)

	Three Months Ended
	March 31, 2021
	U.S.		International		Operating Cost		Other		Consolidated
	(In thousands)
REVENUE:
PRODUCT REVENUE, NET	$	5,647	$	5,567	$	—	$	—	$	11,214
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION		(751)		(811)		—		—		(1,562)
GROSS PROFIT		4,896		4,756		—		—		9,652
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES		725		941		1,538		9		3,213
GENERAL AND ADMINISTRATIVE EXPENSES		241		587		2,396		189		3,413
SALES AND MARKETING EXPENSES		3,278		1,334		143		63		4,818
DEPRECIATION AND AMORTIZATION		—		—		—		638		638
OPERATING EXPENSES		4,244		2,862		4,077		899		12,082
SEGMENT INCOME (LOSS) FROM OPERATIONS		652		1,894		(4,077)		(899)		(2,430)
OTHER INCOME AND EXPENSES, NET		—		—		—		(1,218)		(1,218)
NET LOSS									$	(3,648)

XML

Other Agreements With Ocumension

3 Months Ended

Mar. 31, 2022

Other Agreements With Ocumension [Abstract]

Other Agreements With Ocumension

16. OTHER AGREEMENTS WITH OCUMENSION

Share Purchase Agreement

On April 14, 2021, the Company entered into a Share Purchase Agreement with Ocumension Therapeutics, pursuant to which the Company offered and sold to Ocumension 1,144,945 shares of common stock (the “Shares”), at a purchase price of $8.734044 per Share. The number of Shares sold was equal to 19.9% of the number of shares of common stock outstanding immediately before the closing.

The aggregate gross proceeds from the sale of the Shares were $10,000,000. The Company intends to use the net proceeds from the sale of the Shares to continue to commercialize ILUVIEN® and for general corporate purposes, which may include working capital, capital expenditures, other clinical trial expenditures, acquisitions of new technologies, products or businesses in ophthalmology, and investments.

Pursuant to the Share Purchase Agreement and subject to certain limited exceptions, Ocumension is prohibited from selling, transferring, or otherwise disposing of the Shares for a year following the closing date.

Ocumension is entitled to certain purchase rights if the Company elects to offer or sell new securities in either a private or public offering.

Warrant Subscription Agreement

On April 14, 2021, the Company entered into the warrant agreement with Ocumension Therapeutics pursuant to which Ocumension agreed to issue to the Company 1,000,000 non-transferable warrants granting the Company the right for a period of four years to subscribe to up to an aggregate of 1,000,000 shares of Ocumension stock at the subscription price of HK$23.88 per warrant share (or US$3.07 per warrant share as converted to U.S. Dollars at the exchange rate on April 9, 2021 of 0.12853 U.S. Dollars per HK$), subject to adjustment. (The converted rate is for illustrative purposes only; if the Company exercises the warrants, it will pay the subscription price of HK$23.88 per warrant share in HK$.) The warrants were issued on August 13, 2021, pursuant to the terms of the warrant agreement. The warrants are not and will not be listed on any stock exchange.

‎

XML

Fair Value

3 Months Ended

Mar. 31, 2022

Fair Value [Abstract]

Fair Value

17. FAIR VALUE

The Company applies ASC 820, Fair Value Measurements, in determining the fair value of certain assets and liabilities. Under this standard, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.

In determining fair value, the Company uses various valuation approaches. The hierarchy of those valuation approaches is broken down into three levels based on the reliability of inputs as follows:

Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. An active market for the asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. The valuation under this approach does not entail a significant degree of judgment.

Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include: quoted prices for similar assets or liabilities in active markets, inputs other than quoted prices that are observable for the asset or liability, (e.g., interest rates and yield curves observable at commonly quoted intervals or current market) and contractual prices for the underlying financial instrument, as well as other relevant economic measures.

Level 3 inputs are unobservable inputs for the asset or liability. Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.

The following fair value tables present information about the Company’s assets and liabilities measured at fair value on a recurring basis:

	March 31, 2022
	Level 1		Level 2		Level 3		Total
	(In thousands)
Assets:
Warrant asset (1)	$	—	$	282	$	—	$	282
Assets measured at fair value	$	—	$	282	$	—	$	282

	December 31, 2021
	Level 1		Level 2		Level 3		Total
	(In thousands)
Assets:
Warrant asset (1)	$	—	$	833	$	—	$	833
Assets measured at fair value	$	—	$	833	$	—	$	833

(1) The Company uses the Black-Scholes pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments. Changes in this value each reporting period are reported in the condensed consolidated statement of operations.

XML

Summary Of Significant Accounting Policies (Policy)

3 Months Ended

Mar. 31, 2022

Summary Of Significant Accounting Policies [Abstract]

Adoption Of New Accounting Standard And Accounting Standards Issued But Not Yet Effective

Adoption of New Accounting Standard

In August 2020, the FASB issued Accounting Standards Update (ASU) 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This standard simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The standard requires entities to provide expanded disclosures about the terms and features of convertible instruments and amends certain guidance in ASC 260 on the computation of EPS for convertible instruments and contracts on an entity’s own equity. The standard became effective for the Company on January 1, 2022. The adoption of this guidance did not have a material impact on the Company’s financial statements.

Accounting Standards Issued but Not Yet Effective

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (ASC 326): Measurement of Credit Losses on Financial Instruments. This ASU replaces the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. The standard becomes effective for the Company on January 1, 2023. The Company does not anticipate the adoption of this ASU will have a material impact on its financial statements.

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (ASC 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This standard provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The standard is available until December 31, 2022. The Company does not anticipate the adoption of this ASU will have a material impact on the Company’s financial statements.

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The amendments in this ASU require that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers (ASC 606). The amendments in this ASU are effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company does not anticipate the adoption of this ASU will have a material impact on its financial statements.

XML

Leases (Tables)

3 Months Ended

Mar. 31, 2022

Leases [Abstract]

Summary of Operating Leases Supplemental Balance Sheet Information

	March 31,		December 31,
	2022		2021
	(In thousands)
NON-CURRENT ASSETS:
Right of use assets, net	$	1,624	$	1,710
Total lease assets	$	1,624	$	1,710
CURRENT LIABILITIES:
Accrued expenses	$	323	$	220
NON-CURRENT LIABILITIES:
Other non-current liabilities		2,618		2,735
Total lease liabilities	$	2,941	$	2,955

Schedule of Future Minimum Operating Lease Payments

Years Ending December 31	(In thousands)
2022 (remaining)	$	201
2023		716
2024		687
2025		474
2026		488
Thereafter		1,555
Total		4,121
Less amount representing interest		(1,180)
Present value of minimum lease payments		2,941
Less current portion (as a portion of accrued expenses)		(323)
Non-current portion (as a portion of other non-current liabilities)	$	2,618

Summary of Finance Leases Supplemental Balance Sheet Information

	March 31,		December 31,
	2022		2021
	(In thousands)
NON-CURRENT ASSETS:
Property and equipment, net	$	302	$	392
Total lease assets	$	302	$	392
CURRENT LIABILITIES:
Finance lease obligations	$	251	$	269
NON-CURRENT LIABILITIES:
Finance lease obligations — less current portion		181		225
Total lease liabilities	$	432	$	494

Schedule of Future Minimum Finance Lease Payments

Years Ending December 31	(In thousands)
2022 (remaining)	$	279
2023		236
Total		515
Less amount representing interest		(83)
Present value of minimum lease payments		432
Less current portion		(251)
Non-current portion	$	181

XML

Inventory (Tables)

3 Months Ended

Mar. 31, 2022

Inventory [Abstract]

Schedule of Inventory

	March 31,		December 31,
	2022		2021
	(In thousands)
Component parts (1)	$	157	$	200
Work-in-process (2)		684		1,416
Finished goods		1,611		1,063
Total Inventory	$	2,452	$	2,679

(1)    Component parts inventory consists of manufactured components of the ILUVIEN applicator.

(2)    Work-in-process consists of completed units of ILUVIEN that are undergoing, but have not completed, quality assurance testing or stability testing as required by U.S. or EEA regulatory authorities.

XML

Intangible Asset (Tables)

3 Months Ended

Mar. 31, 2022

Intangible Asset [Abstract]

Future Amortization

Years Ending December 31	(In thousands)
2022 (remaining)	$	1,462
2023		1,940
2024		1,946
2025		1,940
2026		1,940
Thereafter		1,191
Total	$	10,419

XML

Earnings (Loss) Per Share (EPS) (Tables)

3 Months Ended

Mar. 31, 2022

Earnings (Loss) Per Share (EPS) [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

	March 31,
	2022		2021
Series A convertible preferred stock		601,504		601,504
Common stock warrants		—		30,582
Stock options		1,315,161		1,083,124
Total		1,916,665		1,715,210

XML

Equity Incentive Plans (Tables)

3 Months Ended

Mar. 31, 2022

Equity Incentive Plans [Abstract]

Summary of Stock Option Transactions

The following table presents a summary of stock option activity for the three months ended March 31, 2022 and 2021:

	Three Months Ended
	March 31,
	2022			2021
			Weighted			Weighted
			Average			Average
			Exercise			Exercise
	Options		Price ($)	Options		Price ($)
Options outstanding at beginning of period		1,075,795	23.35		939,379	26.72
Grants		283,550	4.84		187,150	5.02
Forfeitures and expirations		(44,184)	22.36		(43,347)	7.80
Exercises		—	—		(58)	6.75
Options outstanding at period end		1,315,161	19.39		1,083,124	23.73
Options exercisable at period end		810,201	27.92		739,466	31.30
Weighted average per share fair value of options granted during the period	$	3.32		$	3.22

Summary of Additional Stock Option Transactions

The following table provides additional information related to outstanding stock options as of March 31, 2022:

					Weighted
			Weighted		Average
			Average		Remaining		Aggregate
			Exercise		Contractual		Intrinsic
	Shares		Price ($)		Term		Value ($)
							(In thousands)
Outstanding		1,315,161		19.39		6.42 years		312
Exercisable		810,201		27.92		4.74 years		36
Outstanding, vested and expected to vest		1,247,294		20.15		6.26 years		277

The following table provides additional information related to outstanding stock options as of December 31, 2021:

					Weighted
			Weighted		Average
			Average		Remaining		Aggregate
			Exercise		Contractual		Intrinsic
	Shares		Price ($)		Term		Value ($)
							(In thousands)
Outstanding		1,075,795		23.35		5.56 years		21
Exercisable		809,837		28.76		4.57 years		5
Outstanding, vested and expected to vest		1,043,347		23.88		5.46 years		19

Summary of Restricted Stock and Restricted Stock Unit Transactions

A summary of restricted stock and restricted stock units (RSU) transactions under the plans are as follows:

	Three Months Ended
	March 31,
	2022				2021
			Weighted				Weighted
			Average				Average
	Restricted		Grant Date		Restricted		Grant Date
	Stock & RSUs		Fair Value ($)		Stock & RSUs		Fair Value ($)
Restricted stock & RSUs outstanding at beginning of period		46,250		5.65		30,086		3.12
Grants		57,500		4.96		45,000		5.01
Vested units		(9,687)		5.01		(25,403)		3.12
Forfeitures		—		—		(10,933)		4.20
Restricted stock & RSUs outstanding at period end		94,063		5.29		38,750		5.01

XML

Segment Information (Tables)

3 Months Ended

Mar. 31, 2022

Segment Information [Abstract]

Summary of Operations by Segment

	Three Months Ended
	March 31, 2022
	U.S.		International		Operating Cost		Other		Consolidated
	(In thousands)
REVENUE:
PRODUCT REVENUE, NET	$	6,919	$	4,979	$	—	$	—	$	11,898
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION		(815)		(865)		—		—		(1,680)
GROSS PROFIT		6,104		4,114		—		—		10,218
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES		1,170		916		1,461		36		3,583
GENERAL AND ADMINISTRATIVE EXPENSES		317		422		2,283		218		3,240
SALES AND MARKETING EXPENSES		4,674		2,004		117		58		6,853
DEPRECIATION AND AMORTIZATION		—		—		—		689		689
OPERATING EXPENSES		6,161		3,342		3,861		1,001		14,365
SEGMENT INCOME (LOSS) FROM OPERATIONS		(57)		772		(3,861)		(1,001)		(4,147)
OTHER INCOME AND EXPENSES, NET		—		—		—		(1,808)		(1,808)
NET LOSS									$	(5,955)

	Three Months Ended
	March 31, 2021
	U.S.		International		Operating Cost		Other		Consolidated
	(In thousands)
REVENUE:
PRODUCT REVENUE, NET	$	5,647	$	5,567	$	—	$	—	$	11,214
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION		(751)		(811)		—		—		(1,562)
GROSS PROFIT		4,896		4,756		—		—		9,652
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES		725		941		1,538		9		3,213
GENERAL AND ADMINISTRATIVE EXPENSES		241		587		2,396		189		3,413
SALES AND MARKETING EXPENSES		3,278		1,334		143		63		4,818
DEPRECIATION AND AMORTIZATION		—		—		—		638		638
OPERATING EXPENSES		4,244		2,862		4,077		899		12,082
SEGMENT INCOME (LOSS) FROM OPERATIONS		652		1,894		(4,077)		(899)		(2,430)
OTHER INCOME AND EXPENSES, NET		—		—		—		(1,218)		(1,218)
NET LOSS									$	(3,648)

XML

Fair Value (Tables)

3 Months Ended

Mar. 31, 2022

Fair Value [Abstract]

Fair Value Of Assets And Liabilities

The following fair value tables present information about the Company’s assets and liabilities measured at fair value on a recurring basis:

	March 31, 2022
	Level 1		Level 2		Level 3		Total
	(In thousands)
Assets:
Warrant asset (1)	$	—	$	282	$	—	$	282
Assets measured at fair value	$	—	$	282	$	—	$	282

	December 31, 2021
	Level 1		Level 2		Level 3		Total
	(In thousands)
Assets:
Warrant asset (1)	$	—	$	833	$	—	$	833
Assets measured at fair value	$	—	$	833	$	—	$	833

(1) The Company uses the Black-Scholes pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments. Changes in this value each reporting period are reported in the condensed consolidated statement of operations.

XML

Nature Of Operations (Narrative) (Details) - ILUVIEN [Member]	Mar. 31, 2022 country
Nature Of Operations [Line Items]
Number of countries in which product has received marketing authorization and reimbursement for the treatment of diabetic macular edema	24
Number of countries in which product is indicated for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies	17
Number of countries authorized for marketing	17
Number of countries with reimbursement approval	5

XML

Summary Of Significant Accounting Policies (Narrative) (Details)	3 Months Ended
	Mar. 31, 2022
Summary Of Significant Accounting Policies [Abstract]
Useful life (in years)	13 years

XML

Revenue Recognition (Narrative) (Details)	3 Months Ended
	Mar. 31, 2022
Revenue Recognition [Abstract]
Period before expiration date returns are accepted	3 months
Period after expiration date returns are accepted	1 year

XML

Leases (Narrative) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Lessee, Lease, Description [Line Items]
Operating lease cost	$ 138,000	$ 118,000
Cash paid for leases	68,000	149,000
Right-of-use asset obtained in exchange for operating lease liability	$ 0	0
Weighted average remaining lease term	6 years 10 months 24 days
Weighted average discount rate, leases	9.50%
Depreciation expense property and equipment under finance leases	$ 94,000	101,000
Finance lease interest expense	14,000	$ 14,000
Cash paid for finance leases	98,000
Property and equipment acquired under finance leases	$ 0
Finance lease, weighted average remaining term	10 months 24 days
Finance lease, weighted average discount rate	9.40%
Minimum
Lessee, Lease, Description [Line Items]
Lease renewal term	1 year
Maximum [Member]
Lessee, Lease, Description [Line Items]
Lease renewal term	8 years

XML

Leases (Summary of Operating Leases Supplemental Balance Sheet Information) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
NON-CURRENT ASSETS:
Total lease assets	$ 1,624	$ 1,710
CURRENT LIABILITIES:
Current liabilities	323	220
NON-CURRENT LIABILITIES:
Non-current liabilities	2,618	2,735
Present value of minimum lease payments	$ 2,941	$ 2,955

XML

Leases (Schedule of Future Minimum Operating Lease Payments) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Leases [Abstract]
2022 (remaining)	$ 201
2023	716
2024	687
2025	474
2026	488
Thereafter	1,555
Total	4,121
Less amount representing interest	(1,180)
Present value of minimum lease payments	2,941	$ 2,955
Less current portion (as a portion of accrued expenses)	(323)	(220)
Non-current portion (as a portion of other non-current liabilities)	$ 2,618	$ 2,735

XML

Leases (Summary of Finance Leases Supplemental Balance Sheet Information) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
NON-CURRENT ASSETS:
Total lease assets	$ 302	$ 392
CURRENT LIABILITIES:
Finance lease obligations	251	269
NON-CURRENT LIABILITIES:
Finance lease obligations — less current portion	181	225
Total lease liabilities	432	494
Property, Plant and Equipment [Member]
NON-CURRENT ASSETS:
Total lease assets	302	$ 392
CURRENT LIABILITIES:
Finance lease obligations	251
NON-CURRENT LIABILITIES:
Finance lease obligations — less current portion	181
Total lease liabilities	$ 432

XML

Leases (Schedule of Future Minimum Finance Lease Payments) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Total lease liabilities	$ 432	$ 494
Less current portion	(251)	(269)
Non-current portion	181	$ 225
Property, Plant and Equipment [Member]
2022 (remaining)	279
2023	236
Total	515
Less amount representing interest	(83)
Total lease liabilities	432
Less current portion	(251)
Non-current portion	$ 181

XML

Going Concern (Narrative) (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2019
Debt Instrument [Line Items]
Accumulated deficit	$ 403,236,000	$ 397,281,000
Cash and cash equivalents	$ 9,946,000	$ 16,510,000
2019 Solar Loan Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, face amount			$ 45,000,000

XML

Inventory (Schedule of Inventory) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Inventory
Component parts	$ 157	$ 200
Work-in-process	684	1,416
Finished goods	1,611	1,063
Total inventory	$ 2,452	$ 2,679

XML

Intangible Asset (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2014	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Gross intangible assets	$ 25,000
Useful life (in years)	13 years
Amortization of intangible assets	$ 489	$ 489
Net intangible assets	$ 10,419			$ 10,897
EyePoint [Member]
Finite-Lived Intangible Assets [Line Items]
Milestone payment after the first product approved by the FDA			$ 25,000

XML

Intangible Asset (Future Amortization) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
2022 (remaining)	$ 1,462
2023	1,940
2024	1,946
2025	1,940
2026	1,940
Thereafter	1,191
Total	$ 10,419	$ 10,897

XML

License Agreements (Narrative) (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended			9 Months Ended
	Mar. 31, 2019	Mar. 31, 2022	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2021	Aug. 01, 2017
Collaborative Arrangement, Co-promotion [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, royalty payable on net revenue, percentage		5.20%		5.20%
Collaborative arrangement, increase in royalty payable on net revenue (as a percentage)		6.00%	6.00%	6.00%	6.00%
Collaborative arrangement, royalty payable on net revenue over threshold, percentage		2.00%
Collaborative arrangement, royalty payable on net revenue, revenue threshold		$ 75,000
Royalty expense		617		$ 584
Accrued royalty expense		617
EyePoint [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, forgiveness of future offset, additional amount	$ 5,000
EyePoint [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Recoverable amount to offset future royalty payments		7,324				$ 15,000
Ocumension [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment from related party		10,000
Revenue from related party		$ 11,048
License agreement, shares purchased		1,000,000
License agreement, share purchase duration		4 years
Deferred revenue related party		$ 300
Ocumension [Member] | Milestone One [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment from related party		$ 89,000

XML

Loan Agreements (Solar Capital Loan Agreement) (Narrative) (Details) - Solar Capital Ltd. - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2019	Feb. 21, 2020	Jan. 05, 2018
2018 Solar Term Loan [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity		$ 45,000
Debt instrument, exit fee	$ 2,000
Debt instrument, exit fee agreement, term	10 years
2018 Solar Term Loan [Member] | Tranche One
Debt Instrument [Line Items]
Milestone revenue requirement	$ 80,000
Milestone period requirement	12 months
2018 Solar Term Loan [Member] | Tranche Two
Debt Instrument [Line Items]
Milestone revenue requirement	$ 100,000
2019 Solar Loan Agreement [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity		45,000		$ 40,000
Line of credit		42,500	$ 2,500
Debt instrument prepayment fee paid		2,300
Debt instrument repayment fee amount, paid		$ 2,200
Second Amendment 2019 Solar Capital Loan Agreement [Member]
Debt Instrument [Line Items]
Loan amendment, minimum revenue amount trailing period	6 months
Loan amendment, period for approval	15 days
Third Amendment 2019 Solar Capital Loan Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	7.65%
Interest rate effective percentage	9.43%
Third Amendment 2019 Solar Capital Loan Agreement [Member] | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	1.78%
2018 Exit Fee Agreement | 2018 Solar Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument, exit fee	$ 2,000
2019 Exit Fee Agreement [Member] | 2019 Solar Loan Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, exit fee	$ 675
Debt instrument, exit fee agreement, term	10 years
Achievement Of Milestone [Member] | 2018 Solar Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument, exit fee	$ 1,000

XML

Loan Agreements (Modification of Debt) (Narrative) (Details) - Solar Capital Ltd. - 2019 Solar Loan Agreement [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2019 USD ($)
Debt Instrument [Line Items]
Debt instrument repayment fee amount, paid	$ 2,200
Debt instrument prepayment fee paid	$ 2,300

XML

Loan Agreements (Paycheck Protection Program) (Narrative) (Details) - PPP Loan [Member] - USD ($)	12 Months Ended
	Dec. 31, 2021	Apr. 22, 2020
Debt Instrument [Line Items]
Debt instrument, face amount		$ 1,778,000
Gain on extinguishment of debt	$ 1,792,000

XML

Loan Agreements (Hercules Loan Agreement And Related Warrant) (Narrative) (Details) - Hercules Technology Growth Capital, Inc. - Warrants 2016 [Member]	Oct. 20, 2016 $ / shares shares
Debt Instrument [Line Items]
Class of warrant or right, number of securities called by warrants or rights (in shares) | shares	30,582
Class of warrant or right, exercise price of warrants or rights (per share) | $ / shares	$ 16.35

XML

Earnings (Loss) Per Share (EPS) (Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	1,916,665	1,715,210
Series A convertible preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	601,504	601,504
Common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)		30,582
Stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	1,315,161	1,083,124

XML

Preferred Stock (Narrative) (Details) - Series A convertible preferred stock [Member] - shares	Mar. 31, 2022	Dec. 31, 2021
Conversion of Stock [Line Items]
Preferred stock, shares issued (in shares)	600,000	600,000
Preferred stock, shares outstanding (in shares)	600,000	600,000

XML

Equity Incentive Plans (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 312	$ 262
Weighted average contractual term	4 years 8 months 26 days		4 years 6 months 25 days
Stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 258	235
Share-based compensation not yet recognized	$ 1,723
Weighted average contractual term	2 years 10 months 17 days
Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for grant (in shares)	686,603
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 8	8
Restricted Stock and RSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	46	$ 19
Share-based compensation not yet recognized	$ 429
Weighted average period	3 years 3 months 14 days

XML

Equity Incentive Plans (Summary of Stock Option Transactions) (Details) - $ / shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Options
Options outstanding at beginning of period (in shares)	1,075,795	939,379
Grants (in shares)	283,550	187,150
Forfeitures and expirations (in shares)	(44,184)	(43,347)
Exercises (in shares)		(58)
Options outstanding at end of period (in shares)	1,315,161	1,083,124
Options exercisable at year end (in shares)	810,201	739,466	809,837
Weighted average per share fair value of options granted during the period (in dollars per share)	$ 3.32	$ 3.22
Weighted Average Exercise Price ($)
Options outstanding at beginning of period (usd per share)	23.35	26.72
Grants (usd per share)	4.84	5.02
Forfeitures and expirations (usd per share)	22.36	7.80
Exercises (usd per share)		6.75
Options outstanding at end of period (usd per share)	19.39	23.73
Options exercisable at year end (usd per share)	$ 27.92	$ 31.30	$ 28.76

XML

Equity Incentive Plans (Summary of Additional Stock Option Transactions) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Outstanding Stock Options
Outstanding, shares (in shares)	1,315,161	1,075,795	1,083,124	939,379
Outstanding, weighted average exercise price (usd per share)	$ 19.39	$ 23.35	$ 23.73	$ 26.72
Outstanding, weighted average remaining contractual term	6 years 5 months 1 day	5 years 6 months 21 days
Outstanding, aggregate intrinsic value	$ 312	$ 21
Exercisable Stock Options
Exercisable, shares (in shares)	810,201	809,837	739,466
Exercisable, weighted average exercise price (usd per share)	$ 27.92	$ 28.76	$ 31.30
Exercisable, weighted average remaining contractual term	4 years 8 months 26 days	4 years 6 months 25 days
Exercisable, aggregate intrinsic value	$ 36	$ 5
Exercisable and expected to vest
Outstanding, vested and expected to vest, shares (in shares)	1,247,294	1,043,347
Outstanding, vested and expected to vest, weighted average exercise price (usd per share)	$ 20.15	$ 23.88
Outstanding, vested and expected to vest, weighted average remaining contractual term	6 years 3 months 3 days	5 years 5 months 15 days
Outstanding, vested and expected to vest, aggregate intrinsic value	$ 277	$ 19

XML

Equity Incentive Plans (Summary of Restricted Stock and Restricted Stock Unit Transactions) (Details) - $ / shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Restricted Stock & RSUs
Restricted stock units & RSUs outstanding at beginning of period (in shares)	46,250	30,086
Grants (in shares)	57,500	45,000
Vested units (in shares)	(9,687)	(25,403)
Forfeitures (in shares)		(10,933)
Restricted stock units outstanding at end of period (in shares)	94,063	38,750
Weighted Average Grant Date Fair Value ($)
Restricted stock units outstanding at beginning of period (usd per share)	$ 5.65	$ 3.12
Grants (usd per share)	4.96	5.01
Vested units (usd per share)	5.01	3.12
Forfeitures (usd per share)		4.20
Restricted stock units & RSUs outstanding end of period (usd per share)	$ 5.29	$ 5.01

XML

Income Taxes (Narrative) (Details) $ in Thousands	Dec. 31, 2021 USD ($)
Federal [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carry-forwards	$ 143,200
State [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carry-forwards	$ 106,700

XML

Segment Information (Narrative) (Details) - United States Segment [Member] - Customer Concentration Risk [Member] - customer	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Sales [Member]
Segment Reporting Information [Line Items]
Number of customers	2	2
Concentration risk percentage	58.00%	50.00%
Accounts Receivable [Member]
Segment Reporting Information [Line Items]
Number of customers	2		2
Concentration risk percentage	58.00%		68.00%

XML

Segment Information (Summary of Operations by Segment) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Segment Reporting Information [Line Items]
PRODUCT REVENUE, NET	$ 11,898	$ 11,214
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION	(1,680)	(1,562)
GROSS PROFIT	10,218	9,652
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES	3,583	3,213
GENERAL AND ADMINISTRATIVE EXPENSES	3,240	3,413
SALES AND MARKETING EXPENSES	6,853	4,818
DEPRECIATION AND AMORTIZATION	689	638
OPERATING EXPENSES	14,365	12,082
LOSS FROM OPERATIONS	(4,147)	(2,430)
OTHER INCOME AND EXPENSES, NET	(1,808)	(1,218)
NET LOSS	(5,955)	(3,648)
United States Segment [Member]
Segment Reporting Information [Line Items]
PRODUCT REVENUE, NET	6,919	5,647
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION	(815)	(751)
GROSS PROFIT	6,104	4,896
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES	1,170	725
GENERAL AND ADMINISTRATIVE EXPENSES	317	241
SALES AND MARKETING EXPENSES	4,674	3,278
OPERATING EXPENSES	6,161	4,244
LOSS FROM OPERATIONS	(57)	652
International Segment [Member]
Segment Reporting Information [Line Items]
PRODUCT REVENUE, NET	4,979	5,567
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION	(865)	(811)
GROSS PROFIT	4,114	4,756
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES	916	941
GENERAL AND ADMINISTRATIVE EXPENSES	422	587
SALES AND MARKETING EXPENSES	2,004	1,334
OPERATING EXPENSES	3,342	2,862
LOSS FROM OPERATIONS	772	1,894
Operating Cost [Member]
Segment Reporting Information [Line Items]
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES	1,461	1,538
GENERAL AND ADMINISTRATIVE EXPENSES	2,283	2,396
SALES AND MARKETING EXPENSES	117	143
OPERATING EXPENSES	3,861	4,077
LOSS FROM OPERATIONS	(3,861)	(4,077)
Other Segments [Member]
Segment Reporting Information [Line Items]
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES	36	9
GENERAL AND ADMINISTRATIVE EXPENSES	218	189
SALES AND MARKETING EXPENSES	58	63
DEPRECIATION AND AMORTIZATION	689	638
OPERATING EXPENSES	1,001	899
LOSS FROM OPERATIONS	(1,001)	(899)
OTHER INCOME AND EXPENSES, NET	$ (1,808)	$ (1,218)

XML

Other Agreements With Ocumension (Narrative) (Details) - Ocumension [Member] $ / shares in Units, $ in Thousands	Apr. 14, 2021 USD ($) $ / shares shares	Apr. 14, 2021 $ / shares shares	Apr. 09, 2021
Related Party Transaction [Line Items]
Partnership agreement, shares sold	1,144,945
Partnership agreement, price per share | $ / shares	$ 8.734044
Partnership agreement, percentage of shares outstanding before closing	19.90%
Partnership agreement, consideration received | $	$ 10,000
Partnership agreement, warrant or rights period	4 years
Shares called by warrants	1,000,000	1,000,000
Exchange rate			0.12853
Class of warrant or right, exercise price of warrants or rights (per share) | (per share)	$ 3.07	$ 23.88

XML

Fair Value (Fair Value Of Assets And Liabilities) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant asset	$ 282
Assets measured at fair value	282
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant asset		$ 833
Assets measured at fair value		833
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant asset	282	833
Assets measured at fair value	$ 282	$ 833